Amedeo Smart

Free Medical Literature Service


 

Amedeo

Liver Diseases

  Free Subscription

Articles published in
J Hepatol
    August 2022
  1. ALAZAWI W
    Myeloid XBP1 links lipid overload with inflammation in NASH: Do advances in basic science have clinical potential?
    J Hepatol. 2022;77:290-292.
    >> Share


  2. EASL Clinical Practice Guidelines on haemochromatosis.
    J Hepatol. 2022;77:479-502.
    >> Share

  3. SCHOMERUS G, Leonhard A, Manthey J, Morris J, et al
    The stigma of alcohol-related liver disease and its impact on healthcare.
    J Hepatol. 2022;77:516-524.
    >> Share

  4. BLACK SM, Zhang Z, Han Y, Zeng C, et al
    Reply to: "Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis".
    J Hepatol. 2022;77:562-563.
    >> Share

  5. BUGIANESI E, Petta S
    NAFLD/NASH.
    J Hepatol. 2022;77:549-550.
    >> Share

  6. BJORNSSON HK, Bjornsson ES
    Reply to: "Can azathioprine prevent infliximab-induced liver injury?"
    J Hepatol. 2022;77:555-556.
    >> Share

  7. ROWE IA, D'Amico G
    Taking a risk-based approach to testing for liver disease in primary care, a step in the right direction.
    J Hepatol. 2022;77:293-295.
    >> Share

  8. JAESCHKE H, Umbaugh DS
    Protection against acetaminophen-induced liver injury with MG53: Muscle-liver axis and necroptosis.
    J Hepatol. 2022;77:560-562.
    >> Share

  9. ABERG F, Luukkonen PK, But A, Salomaa V, et al
    Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score.
    J Hepatol. 2022;77:302-311.
    >> Share

  10. MEUNIER L, Malezieux E, Bozon A, Meszaros M, et al
    Can azathioprine prevent infliximab-induced liver injury?
    J Hepatol. 2022;77:553-555.
    >> Share

    July 2022
  11. TRANAH TH, Ballester MP, Carbonell-Asins JA, Ampuero J, et al
    Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis.
    J Hepatol. 2022 Jul 21. pii: S0168-8278(22)02947.
    >> Share

  12. MARJOT T, Eberhardt CS, Boettler T, Belli LS, et al
    Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper.
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02942.
    >> Share

  13. NELL P, Kattler K, Feuerborn D, Hellwig B, et al
    Identification of an FXR-modulated liver-intestine hybrid state in iPSC-derived hepatocyte-like cells.
    J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02943.
    >> Share

  14. LIU SY, Yuan C, Tong XM
    Antiviral therapy, HBsAg seroclearance and late recurrence of Hepatitis B-related hepatocellular carcinoma.
    J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02938.
    >> Share

  15. ZHAO S, Liao X, Fan R
    An individualized cirrhosis screening strategy might be more cost-effective in the general population.
    J Hepatol. 2022 Jul 14. pii: S0168-8278(22)02937.
    >> Share

  16. MAIMONE S, Tripodi VF, Mazzeo AT
    Response to: A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
    J Hepatol. 2022 Jul 7. pii: S0168-8278(22)02926.
    >> Share

  17. FONTANELLAS A, Avila MA
    Hydroxymethylbilane synthase (aka porphobilinogen deaminase): a novel metabolic tumor suppressor gene in hepatocellular carcinoma.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02921.
    >> Share

  18. BARCENA-VARELA M
    Revealing anti-PD-1 resistance mechanisms in HCC: A path towards novel combination immunotherapies.
    J Hepatol. 2022;77:9-11.
    >> Share

  19. GUO B, Zhou J, Zhao X
    Reply to: "Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease"".
    J Hepatol. 2022;77:260-262.
    >> Share

  20. YU M, Chen Z, Zhou Q, Zhang B, et al
    PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy.
    J Hepatol. 2022;77:140-151.
    >> Share

  21. MARTI-AGUADO D, Clemente-Sanchez A, Bataller R
    Cigarette smoking and liver diseases.
    J Hepatol. 2022;77:191-205.
    >> Share

  22. CHEN YS, Hung YM, Wei JC
    Comment on "Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease".
    J Hepatol. 2022;77:259-260.
    >> Share

  23. MENDEZ-SANCHEZ N, Maris-Gil S, Alonso-Rivera CG
    Latin American Association of Pediatrics (ALAPE) endorses the MAFLD definition of fatty liver disease.
    J Hepatol. 2022;77:249.
    >> Share

    June 2022
  24. VERMA AK, Sharma A, Subramaniyam N, Gandhi CR, et al
    Augmenter of liver regeneration: mitochondrial function and steatohepatitis.
    J Hepatol. 2022 Jun 28. pii: S0168-8278(22)00413.
    >> Share

  25. ALVISI G, Termanini A, Soldani C, Portale F, et al
    Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00370.
    >> Share

  26. JEPSEN P, Reeves H
    Signed, SEALed, detected I'm your patient with advanced fibrosis or cirrhosis!
    J Hepatol. 2022 Jun 20. pii: S0168-8278(22)00369.
    >> Share

  27. BEAUFRERE A, Vilgrain V, Paradis V
    Reply to chao Li et al., Zi-Xiang Chen et al. and Ke-Chun Wang et al.: "Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies".
    J Hepatol. 2022 Jun 19. pii: S0168-8278(22)00374.
    >> Share

  28. SCHLEGEL A, Porte RJ, Dutkowski P
    Corrigendum to 'Protective mechanisms and current clinical evidence of hypothermic oxygenated machine perfusion (HOPE) in preventing post-transplant cholangiopathy' [J Hepatol 76 (2022) 1330-1347].
    J Hepatol. 2022 Jun 16. pii: S0168-8278(22)00353.
    >> Share

  29. BRESCIANI N, Demagny H, Lemos V, Pontanari F, et al
    SLC25A47 is a novel determinant of hepatic mitochondrial function implicated in liver fibrosis.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00364.
    >> Share

  30. LURZ E, Lenz D, Bufler P, Fichtner A, et al
    Letter to the editor - A peditatric hepatologists' perspective.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00363.
    >> Share

  31. JOHANSEN S, Thiele M, Juel HB, Hansen T, et al
    External validation of a genetic risk score that predicts development of alcohol-related cirrhosis.
    J Hepatol. 2022 Jun 13. pii: S0168-8278(22)00365.
    >> Share

  32. SALEM R, Tselikas L, De Baere T
    Interventional treatment of hepatocellular carcinoma.
    J Hepatol. 2022 Jun 12. pii: S0168-8278(22)00229.
    >> Share

  33. TANG Y, Chen Y, Chen HN
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations.
    J Hepatol. 2022 Jun 8. pii: S0168-8278(22)00354.
    >> Share


  34. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.
    J Hepatol. 2022 Jun 7. pii: S0168-8278(22)00346.
    >> Share

  35. GRAVELY AK, Vibert E, Sapisochin G
    Surgical treatment of intrahepatic cholangiocarcinoma.
    J Hepatol. 2022 Jun 5. pii: S0168-8278(22)00017.
    >> Share

  36. ANSTEE QM, Castera L, Loomba R
    Impact of non-invasive biomarkers on hepatology practice: Past, present and future.
    J Hepatol. 2022;76:1362-1378.
    >> Share

  37. CALDERARO J, Seraphin TP, Luedde T, Simon TG, et al
    Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma.
    J Hepatol. 2022;76:1348-1361.
    >> Share

  38. CARACENI P, O'Brien A, Gines P
    Long-term albumin treatment in patients with cirrhosis and ascites.
    J Hepatol. 2022;76:1306-1317.
    >> Share

  39. LISMAN T, Caldwell SH, Intagliata NM
    Haemostatic alterations and management of haemostasis in patients with cirrhosis.
    J Hepatol. 2022;76:1291-1305.
    >> Share

  40. TERRAULT NA, Dufour JF, Schwabe RF, Wong VW, et al
    Breakthroughs in hepatology.
    J Hepatol. 2022;76:1247-1248.
    >> Share

  41. GARDIN A, Remih K, Gonzales E, Andersson ER, et al
    Modern therapeutic approaches to liver-related disorders.
    J Hepatol. 2022;76:1392-1409.
    >> Share

  42. BAJAJ JS, Ng SC, Schnabl B
    Promises of microbiome-based therapies.
    J Hepatol. 2022;76:1379-1391.
    >> Share

  43. GE J, Kim WR, Lai JC, Kwong AJ, et al
    "Beyond MELD" - Emerging strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation.
    J Hepatol. 2022;76:1318-1329.
    >> Share

  44. RATZIU V, Francque S, Sanyal A
    Breakthroughs in therapies for NASH and remaining challenges.
    J Hepatol. 2022;76:1263-1278.
    >> Share

    May 2022
  45. VILLANUEVA C, Torres F, Sarin SK, Shah HA, et al
    Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
    J Hepatol. 2022 May 31. pii: S0168-8278(22)00336.
    >> Share

  46. MOLINA L, Zhu J, Trepo E, Bayard Q, et al
    Biallelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma.
    J Hepatol. 2022 May 27. pii: S0168-8278(22)00333.
    >> Share

  47. KOH JY, Rha MS, Choi SJ, Lee HS, et al
    Identification of a distinct NK-like hepatic T-cell population activated by NKG2C in a TCR-independent manner.
    J Hepatol. 2022 May 26. pii: S0168-8278(22)00335.
    >> Share

  48. POURIKI S, Alexopoulos T, Vasilieva L, Vrioni G, et al
    Rectal colonization by resistant bacteria is associated with infection by the colonizing strain and high mortality in decompensated cirrhosis.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00328.
    >> Share

  49. YOO S, Kim JY, Lim YS, Han S, et al
    Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00329.
    >> Share

  50. DING WX, Ni HM, Waguri S, Komatsu M, et al
    Lack of Hepatic Autophagy Promotes Severity of Liver Injury but Not Steatosis.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00330.
    >> Share

  51. CHU CM, Liaw YF
    Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00324.
    >> Share

  52. HUSAIN A, Chiu YT, Oi-Lin Ng I
    EFNAs are functional predictors for overall survival of hepatocellular carcinoma patients.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00317.
    >> Share

  53. GURI Y, Vosbeck J, Dickenmann M, Jetter A, et al
    Exacerbation of Familial Intrahepatic Cholestasis in Conjunction with COVID-19 Vaccination.
    J Hepatol. 2022 May 16. pii: S0168-8278(22)00313.
    >> Share

  54. SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
    Corrigendum to 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' [J Hepatol 72 (2020) 1028-1029].
    J Hepatol. 2022 May 14. pii: S0168-8278(22)00247.
    >> Share

  55. SUMAZIN P, Peters TL, Sarabia SF, Kim HR, et al
    Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults.
    J Hepatol. 2022 May 13. pii: S0168-8278(22)00275.
    >> Share

  56. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557].
    J Hepatol. 2022 May 9. pii: S0168-8278(22)00248.
    >> Share

  57. WANG KC, Sun LY, Wang MD
    Methodological considerations regarding a gene signature to predict microvascular invasion in hepatocellular carcinoma.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00263.
    >> Share

  58. SCHEINER B, Pinter M
    Reply to: "The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations".
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00266.
    >> Share

  59. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Reply to: 'Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma'.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00265.
    >> Share

  60. SEMMLER G, Mandorfer M
    Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00267.
    >> Share

  61. WANG YZ
    Corrigendum to 'MAFLD supported by 95.45% participants of CSH is NOT representative' [J Hepatol 76 (2022) 481-482].
    J Hepatol. 2022 May 4. pii: S0168-8278(22)00246.
    >> Share

  62. DONNELLY MC, Stableforth W, Krag A, Reuben A, et al
    The negative bidirectional interaction between climate change and the prevalence and care of liver disease: A joint BSG, BASL, EASL, and AASLD commentary.
    J Hepatol. 2022;76:995-1000.
    >> Share

  63. REIG M, Bruix J
    Reply to: "Correspondence on the ".
    J Hepatol. 2022;76:1240-1241.
    >> Share

  64. PETERMANN-ROCHA F, Gray SR, Forrest E, Welsh P, et al
    Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants.
    J Hepatol. 2022;76:1021-1029.
    >> Share

  65. AHMAD J, Barnhart HX, Bonacini M, Ghabril M, et al
    Value of liver biopsy in the diagnosis of drug-induced liver injury.
    J Hepatol. 2022;76:1070-1078.
    >> Share

  66. LEE BP, Cullaro G, Vosooghi A, Yao F, et al
    Discordance in categorization of acute-on-chronic liver failure in the United Network for Organ Sharing database.
    J Hepatol. 2022;76:1122-1126.
    >> Share

  67. SCHEINER B, Balcar L, Nussbaumer RJ, Weinzierl J, et al
    Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.
    J Hepatol. 2022;76:1090-1099.
    >> Share

  68. XU X, Lau WY, Yang T
    The updated BCLC staging system needs further refinement: A surgeon's perspective.
    J Hepatol. 2022;76:1239-1240.
    >> Share

  69. MARJOT T, Ray DW, Tomlinson JW
    Is it time for chronopharmacology in NASH?
    J Hepatol. 2022;76:1215-1224.
    >> Share

  70. MAHMUD N, Chapin S, Goldberg DS, Reddy KR, et al
    Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort.
    J Hepatol. 2022;76:1100-1108.
    >> Share

  71. BOURSIER J, Hagstrom H, Ekstedt M, Moreau C, et al
    Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    J Hepatol. 2022;76:1013-1020.
    >> Share

  72. BERRY P, Kotha S
    Improving end of life care in liver disease.
    J Hepatol. 2022;76:1225-1226.
    >> Share

  73. ELHENCE A, Shalimar
    Liver dysfunction in Barcelona Clinic Liver Cancer-2022 update: Clear as day or still in fog?
    J Hepatol. 2022;76:1236-1237.
    >> Share

  74. GOVAERE O, Petersen SK, Martinez-Lopez N, Wouters J, et al
    Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:1001-1012.
    >> Share

    April 2022
  75. TANTAI X, Yeo YH, Wang J, Ji F, et al
    Reply to: "Evaluating sarcopenia in cirrhosis patients: the role of muscle function".
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00259.
    >> Share

  76. FERNANDEZ J, Prado V, Valdivieso M, Trebicka J, et al
    Response to: Association of rectal colonization by mdros with new infection in cirrhosis.
    J Hepatol. 2022 Apr 30. pii: S0168-8278(22)00257.
    >> Share

  77. LIU C, Zha Z, Zhou C, Chen Y, et al
    Erratum to 'Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma' [J Hepatol 2021 (907-918)].
    J Hepatol. 2022 Apr 27. pii: S0168-8278(22)00240.
    >> Share

  78. LABENZ C, Arslanow A, Nguyen-Tat M, Nagel M, et al
    Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL.
    J Hepatol. 2022 Apr 23. pii: S0168-8278(22)00244.
    >> Share

  79. MAIWALL R, Kumar A, Pasupuleti SSR, Hidam AK, et al
    A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
    J Hepatol. 2022 Apr 20. pii: S0168-8278(22)00239.
    >> Share

  80. ZHANGYUAN G
    Is beta-catenin mutation in murine hepatocytes sufficient to induce liver tumorigenesis?
    J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00242.
    >> Share

  81. JIANG X, Fulte S, Deng F, Chen S, et al
    Lack of VMP1 Impairs Hepatic Lipoprotein Secretion and Promotes Nonalcoholic Steatohepatitis.
    J Hepatol. 2022 Apr 19. pii: S0168-8278(22)00245.
    >> Share

  82. ALKHOURI N, Herring R, Kabler H, Kayali Z, et al
    Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
    J Hepatol. 2022 Apr 16. pii: S0168-8278(22)00235.
    >> Share

  83. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Corrigendum to 'Baveno VII - Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974].
    J Hepatol. 2022 Apr 14. pii: S0168-8278(22)00198.
    >> Share

  84. CHUAH S, Lee J, Song Y, Kim HD, et al
    Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
    J Hepatol. 2022 Apr 14. pii: S0168-8278(22)00233.
    >> Share

  85. LI C, Ouyang W, Yang T
    The association of microvascular invasion with satellite nodule, tumor multiplicity, tumor encapsulation and resection margin of hepatocellular carcinoma.
    J Hepatol. 2022 Apr 10. pii: S0168-8278(22)00228.
    >> Share

  86. CHAPIRO J
    Translating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma.
    J Hepatol. 2022 Apr 10. pii: S0168-8278(22)00227.
    >> Share

  87. YANG H, Bae SH, Nam H, Lee HL, et al
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00208.
    >> Share

  88. RUSSO FP, Vigano M, Stock P, Ferrarese A, et al
    HBV-positive and HIV-positive organs in transplantation: a clinical guide for the hepatologist.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00175.
    >> Share

  89. YANG T, Poenisch M, Khanal R, Hu Q, et al
    Corrigendum to 'Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model' [J Hepatol (2021) 1420-1433].
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00197.
    >> Share

  90. TSAY HC, Yuan Q, Balakrishnan A, Kaiser M, et al
    Corrigendum to: 'Hepatocyte-specific suppression of microRNA-221-3p mitigates liver fibrosis' [J Hepatol (2019) 722-734].
    J Hepatol. 2022 Apr 6. pii: S0168-8278(22)00196.
    >> Share

  91. DEMIR M, Lang S, Hartmann P, Duan Y, et al
    The fecal mycobiome in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:788-799.
    >> Share

  92. MEHAL WZ, Schwabe RF
    A disease-promoting role of the intestinal mycobiome in non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:765-767.
    >> Share

  93. CHALASANI N, Bonkovsky HL, Stine JG, Gu J, et al
    Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study.
    J Hepatol. 2022;76:832-840.
    >> Share

  94. BYRNE CD, Newsome PN, Noureddin M
    Why are there no strategies for NAFLD?
    J Hepatol. 2022;76:763-764.
    >> Share

  95. LAZARUS JV, Mark HE, Villota-Rivas M, Palayew A, et al
    The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?
    J Hepatol. 2022;76:771-780.
    >> Share

  96. FROMME M, Schneider CV, Trautwein C, Brunetti-Pierri N, et al
    Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder.
    J Hepatol. 2022;76:946-958.
    >> Share

  97. NOUREDDIN M, Truong E, Gornbein JA, Saouaf R, et al
    MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
    J Hepatol. 2022;76:781-787.
    >> Share

  98. SCORLETTI E, Carr RM
    A new perspective on NAFLD: Focusing on lipid droplets.
    J Hepatol. 2022;76:934-945.
    >> Share

    March 2022
  99. BARSCH M, Salie H, Schlaak AE, Zhang Z, et al
    T cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
    J Hepatol. 2022 Mar 31. pii: S0168-8278(22)00180.
    >> Share

  100. WANG S, Wu Q, Chen T, Su R, et al
    Blocking CD47 promotes anti-tumor immunity through CD103+ dendritic cell-NK cell axis in murine hepatocellular carcinoma model.
    J Hepatol. 2022 Mar 31. pii: S0168-8278(22)00179.
    >> Share

  101. LI D, Yi C, Huang H, Li J, et al
    Hepatocyte specific depletion of Nnmt protects the mice from non-alcoholic steatohepatitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00191.
    >> Share

  102. BOWLUS CL, Galambos MR, Aspinall RJ, Hirschfield GM, et al
    A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
    J Hepatol. 2022 Mar 30. pii: S0168-8278(22)00187.
    >> Share

  103. ZANETTO A, Campello E, Bulato C, Gavasso S, et al
    Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death.
    J Hepatol. 2022 Mar 29. pii: S0168-8278(22)00177.
    >> Share

  104. JALAN R, Rose CF
    Heretical thoughts into Hepatic Encephalopathy.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00183.
    >> Share

  105. BEAULANT A, Dia M, Pillot B, Chauvin MA, et al
    Endoplasmic reticulum-mitochondria miscommunication is an early and causal trigger of hepatic insulin resistance and steatosis.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00185.
    >> Share

  106. LIN P, Yang H
    EFNA3 is a prognostic biomarker for the overall survival of hepatocellular carcinoma patients.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00176.
    >> Share

  107. TAPPER EB, Essien UR, Zhao Z, Ufere NN, et al
    Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00116.
    >> Share

  108. MAGYAR CTJ, Beldi G, Banz V
    Impact of MELD 30-allocation policy on liver transplant outcomes in Italy: Considerations.
    J Hepatol. 2022 Mar 28. pii: S0168-8278(22)00186.
    >> Share

  109. TANTAI X, Yeo YH, Wang J, Ji F, et al
    Reply to: "Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis".
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00182.
    >> Share

  110. YANG Y, Ouyang J, Zhou Y, Zhou J, et al
    The CRAFITY score: a promising prognostic predictor for patients with hepatocellular carcinoma treated with tyrosine kinase inhibitor and immunotherapy combinations.
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00188.
    >> Share

  111. XIONG J, Tian Y
    Evaluating sarcopenia in cirrhosis patients: the role of muscle function.
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00190.
    >> Share

  112. TRIPODI A
    Cirrhosis. What are all those factor VIII and protein C for?
    J Hepatol. 2022 Mar 26. pii: S0168-8278(22)00189.
    >> Share

  113. SCHWARZ C, Chromy D, Bangert C, Schwarz M, et al
    Immediate-type hypersensitivity reaction to bulevirtide and successful desensitization in a patient with HBV/HDV-associated compensated cirrhosis.
    J Hepatol. 2022 Mar 16. pii: S0168-8278(22)00172.
    >> Share

  114. SUN R, Zhang Z, Bao R, Guo X, et al
    Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00139.
    >> Share

  115. WANG Q, Zhou H, Bu Q, Wei S, et al
    Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
    J Hepatol. 2022 Mar 12. pii: S0168-8278(22)00140.
    >> Share

  116. NAKATSUKA T, Tateishi R, Nakagomi R, Minami T, et al
    Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00138.
    >> Share

  117. WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
    Corrigendum to: 'A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers' [J Hepatol 2022 (76) 275-282].
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00117.
    >> Share

  118. TORGERSEN J, Taddei TH, Lo Re V 3rd
    Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?"
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00132.
    >> Share

  119. SINGH SP, Jindal A
    Association of rectal colonisation by MDROs with new infection in cirrhosis.
    J Hepatol. 2022 Mar 9. pii: S0168-8278(22)00135.
    >> Share

  120. SUN X, Wu J, Liu L, Chen Y, et al
    Transcriptional switch of hepatocytes initiates macrophage recruitment and T cell suppression in endotoxemia.
    J Hepatol. 2022 Mar 8. pii: S0168-8278(22)00136.
    >> Share

  121. INNES H, Morling JR, Buch S, Hamill V, et al
    Performance of routine risk scores for predicting cirrhosis-related morbidity in the community.
    J Hepatol. 2022 Mar 7. pii: S0168-8278(22)00129.
    >> Share

  122. XU L, Yang Y, Wen Y, Jeong JM, et al
    Hepatic recruitment of eosinophils and their protective function during acute liver injury.
    J Hepatol. 2022 Mar 5. pii: S0168-8278(22)00131.
    >> Share

  123. LOESCH R, Caruso S, Paradis V, Godard C, et al
    Deleting the beta-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.
    J Hepatol. 2022 Mar 4. pii: S0168-8278(22)00130.
    >> Share


  124. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis.
    J Hepatol. 2022 Mar 2. pii: S0168-8278(21)02033.
    >> Share

  125. SPELIOTES EK, George J
    Metabolic and genetic contributions to NAFLD: Really distinct and homogeneous?
    J Hepatol. 2022;76:498-500.
    >> Share

  126. DING WX, Sancho-Bru P
    SOX9 acts downstream of YAP to decide liver cell fate and tumor types.
    J Hepatol. 2022;76:503-505.
    >> Share

  127. MARTINEZ J, Hernandez-Gea V, Albillos A
    Reply to: "Potential novel approaches to prevent the risk of infection in patients with variceal bleeding".
    J Hepatol. 2022;76:752-753.
    >> Share

  128. SHALTOUT I, Alkandari H, Fouad Y, Hamed AE, et al
    Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease.
    J Hepatol. 2022;76:739-740.
    >> Share

  129. DEPRET F, Bouam S, Schwarzinger M, Mallet V, et al
    Reply to: "Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: A case control study from the prospective COVID-ICU database".
    J Hepatol. 2022;76:744-747.
    >> Share

  130. EL-SHABRAWI M, Memon I, Attia D, El-Koofy NM, et al
    The International Society of Tropical Paediatrics (ISTP) endorses the redefinition of fatty liver disease.
    J Hepatol. 2022;76:738-739.
    >> Share

  131. LIU D, Zhang Q, Bai P, Zhao J, et al
    Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:740-742.
    >> Share

  132. WEBER ND, Martinez-Garcia J, Gonzalez-Aseguinolaza G
    Comment on "Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3".
    J Hepatol. 2022;76:749-751.
    >> Share

  133. ALABSAWY E, Shalimar, Jalan R
    Potential novel approaches to prevent the risk of infection in patients with variceal bleeding.
    J Hepatol. 2022;76:751-752.
    >> Share


  134. Expression of concern: "The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis" by Ivana Ilic and Tamara Milovanovic [J Hepatol 73 (2020) 701-702].
    J Hepatol. 2022;76:758.
    >> Share

  135. GUO B, Guo Y, Nima Q, Feng Y, et al
    Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease.
    J Hepatol. 2022;76:518-525.
    >> Share

  136. REIG M, Forner A, Rimola J, Ferrer-Fabrega J, et al
    BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.
    J Hepatol. 2022;76:681-693.
    >> Share

  137. KRONSTEN VT, Tranah TH, Pariante C, Shawcross DL, et al
    Gut-derived systemic inflammation as a driver of depression in chronic liver disease.
    J Hepatol. 2022;76:665-680.
    >> Share

  138. RINELLA ME, Dufour JF, Anstee QM, Goodman Z, et al
    Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    J Hepatol. 2022;76:536-548.
    >> Share

  139. RATZIU V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, et al
    EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
    J Hepatol. 2022;76:506-517.
    >> Share

  140. LUUKKONEN PK, Qadri S, Ahlholm N, Porthan K, et al
    Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease.
    J Hepatol. 2022;76:526-535.
    >> Share

  141. YIP TC, Lee HW, Chan WK, Wong GL, et al
    Asian perspective on NAFLD-associated HCC.
    J Hepatol. 2022;76:726-734.
    >> Share

    February 2022
  142. HUSAIN A, Chiu YT, Sze KM, Ho DW, et al
    Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma.
    J Hepatol. 2022 Feb 25. pii: S0168-8278(22)00125.
    >> Share

  143. NINGARHARI M, Caruso S, Hirsch TZ, Bayard Q, et al
    Corrigendum to: 'Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target' [J Hepatol 2021 (74) 1155-1166].
    J Hepatol. 2022 Feb 24. pii: S0168-8278(22)00061.
    >> Share

  144. WEI CY, Zhu MX, Zhang PF, Huang XY, et al
    PKCalpha/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
    J Hepatol. 2022 Feb 24. pii: S0168-8278(22)00126.
    >> Share

  145. MONTANARI NR, Ramirez R, Aggarwal A, van Buuren N, et al
    Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Feb 23. pii: S0168-8278(22)00123.
    >> Share

  146. PATIDAR KR, Naved MA, Grama A, Adibuzzaman M, et al
    Acute Kidney Disease is Common and Associated with Poor Outcomes in Patients with Cirrhosis and Acute Kidney Injury.
    J Hepatol. 2022 Feb 22. pii: S0168-8278(22)00115.
    >> Share

  147. OLLIVIER-HOURMAND I, Allaire M, Cervoni JP
    Management of portal hypertension in patients treated with Atezolizumab and Bevacizumab for hepatocellular carcinoma.
    J Hepatol. 2022 Feb 16. pii: S0168-8278(22)00079.
    >> Share

  148. SCHEINER B, Pinter M
    The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy - authors' reply.
    J Hepatol. 2022 Feb 14. pii: S0168-8278(22)00073.
    >> Share

  149. FONDEVILA MF, Fernandez U, Heras V, Parracho T, et al
    Inhibition of carnitine palmitoyl-transferase 1A in hepatic stellate cells protects against fibrosis.
    J Hepatol. 2022 Feb 12. pii: S0168-8278(22)00077.
    >> Share

  150. JEONG J, Tanaka M, Iwakiri Y
    Hepatic lymphatic vascular system in health and disease.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00071.
    >> Share

  151. MUELLER PP, Chen Q, Ayer T, Nemutlu G, et al
    Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00074.
    >> Share

  152. ZHOU SL, Zhou ZJ, Hu ZQ, Song CL, et al
    Corrigendum to 'Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence' [J Hepatol 71 (2019) 1152-63].
    J Hepatol. 2022 Feb 9. pii: S0168-8278(22)00026.
    >> Share

  153. ZINGONI A, Banales JM
    PIGR-enriched circulating vesicles contributes to hepatocellular carcinoma aggressiveness.
    J Hepatol. 2022 Feb 8. pii: S0168-8278(22)00070.
    >> Share

  154. ZENG Q, Klein C, Caruso S, Maille P, et al
    Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology.
    J Hepatol. 2022 Feb 7. pii: S0168-8278(22)00031.
    >> Share

  155. SINGAL AG, Zhang E, Narasimman M, Rich NE, et al
    HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis.
    J Hepatol. 2022 Feb 6. pii: S0168-8278(22)00068.
    >> Share

  156. GHALLAB A, Hassan R, Hofmann U, Friebel A, et al
    Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity.
    J Hepatol. 2022 Feb 4. pii: S0168-8278(22)00062.
    >> Share

  157. JACHS M, Scheiner B, Pinter M
    Letter to the editor: Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection.
    J Hepatol. 2022 Feb 3. pii: S0168-8278(22)00030.
    >> Share

  158. ENGELMANN C, Bruns T, Berg T
    Reply to: "G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!"
    J Hepatol. 2022;76:473-475.
    >> Share

  159. KIM D, Ahmed A
    Reply to: "NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver".
    J Hepatol. 2022;76:477-478.
    >> Share

  160. FOUAD YM, Mendez-Sanchez N, Zheng MH
    One not like the other: The weakness of the blood sugar-MAFLD analogy.
    J Hepatol. 2022;76:482-484.
    >> Share

  161. DE A, Ahmad N, Mehta M, Singh P, et al
    NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver.
    J Hepatol. 2022;76:475-477.
    >> Share

  162. JINDAL A, Sarin SK
    G-CSF in acute-on-chronic liver failure - Art of 'patient selection' is paramount!
    J Hepatol. 2022;76:472-473.
    >> Share

  163. WANG YZ
    MAFLD supported by 95.45% participants of CSH is NOT representative.
    J Hepatol. 2022;76:481-482.
    >> Share

  164. BJORNSSON ES, Andrade RJ
    Long-term sequelae of drug-induced liver injury.
    J Hepatol. 2022;76:435-445.
    >> Share

  165. DANA J, Debray D, Beaufrere A, Hillaire S, et al
    Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.
    J Hepatol. 2022;76:420-434.
    >> Share

  166. MALLET V, Parlati L, Martinino A, Scarano Pereira JP, et al
    Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus.
    J Hepatol. 2022;76:265-274.
    >> Share

  167. FOERSTER F, Gairing SJ, Muller L, Galle PR, et al
    NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options.
    J Hepatol. 2022;76:446-457.
    >> Share

    January 2022
  168. YANG M, Wu X, Hu J, Wang Y, et al
    COMMD10 inhibits HIF1alpha/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma.
    J Hepatol. 2022 Jan 28. pii: S0168-8278(22)00022.
    >> Share

  169. BRUNT EM, Clouston AD, Goodman Z, Guy C, et al
    Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00024.
    >> Share

  170. RIDOLA L, Gioia S, Faccioli J, Riggio O, et al
    Gut liver muscle brain axis: a comprehensive viewpoint on prognosis in cirrhosis.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00016.
    >> Share

  171. LIMON-MIRO AT, Jackson CD, Eslamparast T, Yamanaka-Okumura H, et al
    Predicted estimates of resting energy expenditure have limited clinical utility in patients with cirrhosis.
    J Hepatol. 2022 Jan 25. pii: S0168-8278(22)00018.
    >> Share

  172. PRADO V, Hernandez-Tejero M, Mucke MM, Marco F, et al
    Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis.
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00013.
    >> Share

  173. BUONOMO E, Mei S, Guinn S, Leo I, et al
    Liver Stromal Cells Restrict Macrophage Maturation and Stromal IL-6 Limits the Differentiation of Cirrhosis-linked Macrophages.
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00007.
    >> Share

  174. WONG YJ, Nguyen MH
    Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?
    J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00008.
    >> Share

  175. ZHOU HF, Yang W, Zhou WZ
    The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy.
    J Hepatol. 2022 Jan 18. pii: S0168-8278(22)00004.
    >> Share

  176. D'AMICO G, Bernardi M, Angeli P
    Corrigendum to 'Towards a new definition of decompensated cirrhosis' [J Hepatol 76 (2022) 202-207].
    J Hepatol. 2022 Jan 5. pii: S0168-8278(21)02300.
    >> Share

  177. CRAMER T, Vaupel P
    Severe hypoxia is a typical characteristic of human hepatocellular carcinoma: Scientific fact or fallacy?
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02305.
    >> Share

  178. JAGADISAN B, Dhawan A
    Emergencies in Pediatric hepatology.
    J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02304.
    >> Share

  179. MALLET V, Schwarzinger M
    Reply to: "Association of chronic liver disease with the prognosis of COVID-19 patients".
    J Hepatol. 2022;76:229-230.
    >> Share

  180. LONG J, Sang X, Zhao H
    Association of chronic liver disease with the prognosis of COVID-19 patients.
    J Hepatol. 2022;76:228-229.
    >> Share

  181. SHROFF H, Satapathy SK, Crawford JM, Todd NJ, et al
    Liver injury following SARS-CoV-2 vaccination: A multicenter case series.
    J Hepatol. 2022;76:211-214.
    >> Share

  182. SCHUPPAN D, Myneni S, Surabattula R
    Liquid biomarkers for fibrotic NASH - progress in a complex field.
    J Hepatol. 2022;76:5-7.
    >> Share


  183. Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update".
    J Hepatol. 2022;76:251-252.
    >> Share

  184. THULUVATH PJ, Li F
    Reply to: "Universal definition and prognostication in acute-on- chronic liver failure - an unmet need!"
    J Hepatol. 2022;76:242-243.
    >> Share

  185. TURON F, Lisman T, Carlos-Garcia-Pagan J
    Reply to: Correspondence on "Predicting portal thrombosis in cirrosis: A prospective study of clinical, ultrasonographic and hemostatic factors".
    J Hepatol. 2022;76:227-228.
    >> Share

  186. LI B, He Q, Lu G, Hong C, et al
    Minor role of hemostatic alternation in portal vein thrombosis pathogenesis revealed by global measurement.
    J Hepatol. 2022;76:225-227.
    >> Share

  187. VAN KLEEF LA, Sonneveld MJ, de Man RA, de Knegt RJ, et al
    Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease - implications for the clinical utility of the EASL NIT guideline.
    J Hepatol. 2022;76:245-246.
    >> Share

  188. VERMA N, Mehtani R, Duseja A
    Universal definition and prognostication in acute-on-chronic liver failure - an unmet need!
    J Hepatol. 2022;76:241-242.
    >> Share

  189. LIU Y, Liu C, Li J, Kim TH, et al
    Risk stratification of decompensation using liver stiffness and platelet counts in compensated advanced chronic liver disease (CHESS2102).
    J Hepatol. 2022;76:248-250.
    >> Share

  190. COREY KE, Pitts R, Lai M, Loureiro J, et al
    ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD.
    J Hepatol. 2022;76:25-33.
    >> Share

  191. DA SILVA LIMA N, Fondevila MF, Novoa E, Buque X, et al
    Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function.
    J Hepatol. 2022;76:11-24.
    >> Share

  192. VOGEL A, Saborowski A
    Medical therapy of HCC.
    J Hepatol. 2022;76:208-210.
    >> Share

  193. LOOSEN SH, Kostev K, Keitel V, Tacke F, et al
    An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD.
    J Hepatol. 2022;76:247-248.
    >> Share

  194. SINGAL AG, El-Serag HB
    Rational HCC screening approaches for patients with NAFLD.
    J Hepatol. 2022;76:195-201.
    >> Share

  195. BJORNSSON HK, Gudbjornsson B, Bjornsson ES
    Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
    J Hepatol. 2022;76:86-92.
    >> Share

  196. SEKIBA K, Otsuka M, Funato K, Miyakawa Y, et al
    HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA.
    J Hepatol. 2022;76:53-62.
    >> Share

  197. ZHANG IW, Curto A, Lopez-Vicario C, Casulleras M, et al
    Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure.
    J Hepatol. 2022;76:93-106.
    >> Share

  198. GHELFI J, Brusset B, Thony F, Decaens T, et al
    Successful management of refractory ascites in non-TIPSable patients using percutaneous thoracic duct stenting.
    J Hepatol. 2022;76:216-218.
    >> Share

    December 2021
  199. SCHEINER B, Pinter M
    Letter to the Editor: Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet? - authors' reply.
    J Hepatol. 2021 Dec 31. pii: S0168-8278(21)02302.
    >> Share

  200. DE FRANCHIS R, Bosch J, Garcia-Tsao G, Reiberger T, et al
    Baveno VII - Renewing consensus in portal hypertension.
    J Hepatol. 2021 Dec 30. pii: S0168-8278(21)02299.
    >> Share

  201. BELLI LS, Perricone G, Jalan R
    Reply to: Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation. Reply letter.
    J Hepatol. 2021 Dec 28. pii: S0168-8278(21)02293.
    >> Share

  202. WANG H, Zhang S, Zhang Y, Jia J, et al
    Corrigendum to 'TAZ is indispensable for c-MYC-induced hepatocarcinogenesis' [J Hepatol (2022) 123-134].
    J Hepatol. 2021 Dec 26. pii: S0168-8278(21)02248.
    >> Share

  203. GARRIDO A, Kim E, Teijeiro A, Sanchez PS, et al
    Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis.
    J Hepatol. 2021 Dec 24. pii: S0168-8278(21)02294.
    >> Share

  204. SOUNDARARAJAN R, Gupta P
    Reply to "Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead".
    J Hepatol. 2021 Dec 23. pii: S0168-8278(21)02292.
    >> Share

  205. BEAUMONT E, Larochette V, Preisser L, Miot C, et al
    IL-26 inhibits hepatitis C virus replication in hepatocytes.
    J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02253.
    >> Share

  206. TEY SK, Wong SWK, Tung Chan JY, Mao X, et al
    Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma.
    J Hepatol. 2021 Dec 16. pii: S0168-8278(21)02245.
    >> Share

  207. WANG X, Zeldin S, Shi H, Zhu C, et al
    TAZ-induced Cybb contributes to liver tumor formation in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Dec 10. pii: S0168-8278(21)02242.
    >> Share

  208. CHENG AL, Qin S, Ikeda M, Galle PR, et al
    Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
    J Hepatol. 2021 Dec 10. pii: S0168-8278(21)02241.
    >> Share

  209. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    Corrigendum to 'An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs' [J Hepatol 2021;75(3):572-581].
    J Hepatol. 2021 Dec 9. pii: S0168-8278(21)02219.
    >> Share

  210. KASSIANIDES C, Dusheiko G, Di Bisceglie A, Hoofnagle JH, et al
    Michael Charles Kew - Frontrunner in Hepatology.
    J Hepatol. 2021 Dec 6. pii: S0168-8278(21)02224.
    >> Share

  211. KADONO K, Kageyama S, Nakamura K, Hirao H, et al
    Myeloid ikaros-SIRT1 signaling axis regulates hepatic inflammation and pyroptosis in ischemia-stressed mouse and human liver.
    J Hepatol. 2021 Dec 3. pii: S0168-8278(21)02235.
    >> Share

  212. NACHIT M, Kwanten WJ, Francque S
    Reply to: "Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?"
    J Hepatol. 2021;75:1513-1514.
    >> Share

  213. LUEDDE T, Baumann U, Keitel V
    Reply to: "Multiple investigations for a very common disorder: Finding the right balance in NAFLD".
    J Hepatol. 2021;75:1502-1503.
    >> Share

  214. WONG VW, Lazarus JV
    Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change.
    J Hepatol. 2021;75:1267-1270.
    >> Share

  215. POHL J, Gebauer B, Gebert P, Tacke F, et al
    Predicting survival after TIPS: Child Pugh score is not inferior to MELD and FIPS score - back to basics?
    J Hepatol. 2021;75:1505-1506.
    >> Share

  216. MATTHEWS C, Cross TJS
    Before we can find an evidence base for HCC surveillance, we need to define our target demographic.
    J Hepatol. 2021;75:1494-1495.
    >> Share

  217. KOTHA S, Berry P
    Multiple investigations for a very common disorder: Finding the right balance in NAFLD.
    J Hepatol. 2021;75:1501-1502.
    >> Share

  218. CADENAS-SANCHEZ C, Idoate F, Villanueva A, Cabeza R, et al
    Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist in childhood?
    J Hepatol. 2021;75:1511-1513.
    >> Share

  219. NIELSEN MJ, Leeming DJ, Goodman Z, Friedman S, et al
    Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
    J Hepatol. 2021;75:1292-1300.
    >> Share

  220. IOANNOU GN
    Epidemiology and risk-stratification of NAFLD-associated HCC.
    J Hepatol. 2021;75:1476-1484.
    >> Share

  221. YANG T, Poenisch M, Khanal R, Hu Q, et al
    Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model.
    J Hepatol. 2021;75:1420-1433.
    >> Share

  222. HSU CL, Duan Y, Fouts DE, Schnabl B, et al
    Intestinal virome and therapeutic potential of bacteriophages in liver disease.
    J Hepatol. 2021;75:1465-1475.
    >> Share

  223. KIM D, Konyn P, Sandhu KK, Dennis BB, et al
    Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    J Hepatol. 2021;75:1284-1291.
    >> Share

  224. ENGELMANN C, Herber A, Franke A, Bruns T, et al
    Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study).
    J Hepatol. 2021;75:1346-1354.
    >> Share

  225. GADALETA RM, Moschetta A
    Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver.
    J Hepatol. 2021;75:1440-1451.
    >> Share

  226. D'AMICO G, Maruzzelli L, Airoldi A, Petridis I, et al
    Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology.
    J Hepatol. 2021;75:1355-1366.
    >> Share

    November 2021
  227. CABIBBO G, Singal AG
    The quest for precision oncology with immune checkpoint inhibitors and hepatocellular carcinoma.
    J Hepatol. 2021 Nov 26. pii: S0168-8278(21)02226.
    >> Share

  228. LIU Y, Zhuo S, Zhou Y, Ma L, et al
    Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02182.
    >> Share

  229. D'AVOLA D, Granito A, de la Torre-Alaez M, Piscaglia F, et al
    The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02185.
    >> Share

  230. SABOO K, Petrakov NV, Shamsaddini A, Fagan A, et al
    Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02183.
    >> Share

  231. DING GY, Ma JQ, Yun JP, Chen X, et al
    Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Nov 15. pii: S0168-8278(21)02178.
    >> Share

  232. TANTAI X, Liu Y, Yeo YH, Praktiknjo M, et al
    Effect of sarcopenia on survival in patients with cirrhosis: A systematic review and meta-analysis.
    J Hepatol. 2021 Nov 13. pii: S0168-8278(21)02174.
    >> Share

  233. HUO TI, Liao JI, Ho SY
    Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?
    J Hepatol. 2021 Nov 12. pii: S0168-8278(21)02176.
    >> Share

  234. XU X, Nan Y
    Reply to: Correspondence on "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease".
    J Hepatol. 2021 Nov 11. pii: S0168-8278(21)02170.
    >> Share

  235. RAVAIOLI M, Lai Q, Sessa M, Ghinolfi D, et al
    Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
    J Hepatol. 2021 Nov 10. pii: S0168-8278(21)02166.
    >> Share

  236. PAVLIDES M, Francis S, Barnes E
    Abbreviated MRI to screen for HCC in patients with cirrhosis. A step forward but a long road ahead.
    J Hepatol. 2021 Nov 8. pii: S0168-8278(21)02169.
    >> Share

  237. COLOMBO M, Barouki R
    Expanding the liver exposome: should hepatologists care about air pollution?
    J Hepatol. 2021 Nov 5. pii: S0168-8278(21)02165.
    >> Share

  238. SANGRO B, Bruix J, Chan SL, Galle PR, et al
    Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02162.
    >> Share

  239. HAN Y, Black S, Gong Z, Chen Z, et al
    Membrane-delimited signaling and cytosolic action of MG53 preserve hepatocyte integrity during drug-induced liver injury.
    J Hepatol. 2021 Nov 1. pii: S0168-8278(21)02154.
    >> Share

  240. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD" and "Transient elastography in chronic liver disease: Beware of the cut-offs!"
    J Hepatol. 2021;75:1247.
    >> Share

  241. GUPTA P, Sharma V, Kalra N
    Reply to: "Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening".
    J Hepatol. 2021;75:1259-1260.
    >> Share

  242. VILLANUEVA C, Bosch J
    Reply to: "First things first! Can bacterial infections be considered as decompensating events per se?"
    J Hepatol. 2021;75:1242-1243.
    >> Share

  243. KUTAIBA N, Ardalan Z
    Risk factors and screening intervals are crucial for evaluating the cost effectiveness of abbreviated MRI in HCC screening.
    J Hepatol. 2021;75:1258-1259.
    >> Share

  244. JI Y, Li J, He Q, Zhou L, et al
    Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD.
    J Hepatol. 2021;75:1243-1245.
    >> Share

  245. CRISTOFERI L, Nardi A, Carbone M
    Transient elastography in chronic liver disease: Beware of the cut-offs!
    J Hepatol. 2021;75:1245-1246.
    >> Share

  246. REICHERT MC, Ripoll C
    First things first! Can bacterial infections be considered as decompensating events per se?
    J Hepatol. 2021;75:1241-1242.
    >> Share

  247. LANGE NF, Radu P, Dufour JF
    Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention.
    J Hepatol. 2021;75:1217-1227.
    >> Share

  248. HAGSTROM H, Simon TG, Roelstraete B, Stephansson O, et al
    Maternal obesity increases the risk and severity of NAFLD in offspring.
    J Hepatol. 2021;75:1042-1048.
    >> Share

  249. RUIZ-BLAZQUEZ P, Pistorio V, Fernandez-Fernandez M, Moles A, et al
    The multifaceted role of cathepsins in liver disease.
    J Hepatol. 2021;75:1192-1202.
    >> Share

  250. SIMON TG, Roelstraete B, Hartjes K, Shah U, et al
    Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.
    J Hepatol. 2021;75:1034-1041.
    >> Share

  251. WANG Q, Liang N, Yang T, Li Y, et al
    DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer.
    J Hepatol. 2021;75:1142-1153.
    >> Share

  252. JALAN R, Gustot T, Fernandez J, Bernal W, et al
    'Equity' and 'Justice' for patients with acute-on chronic liver failure: A call to action.
    J Hepatol. 2021;75:1228-1235.
    >> Share

  253. FERRER-FABREGA J, Sampson-Davila J, Forner A, Sapena V, et al
    Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival.
    J Hepatol. 2021;75:1154-1163.
    >> Share

  254. RASMUSSEN DN, Thiele M, Johansen S, Kjaergaard M, et al
    Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.
    J Hepatol. 2021;75:1017-1025.
    >> Share

  255. LI F, Thuluvath PJ
    EASL-CLIF criteria outperform NACSELD criteria for diagnosis and prognostication in ACLF.
    J Hepatol. 2021;75:1096-1103.
    >> Share

    October 2021
  256. CHAO X, Wang S, Fulte S, Ma X, et al
    Hepatocytic p62 suppresses ductular reaction and tumorigenesis in mouse livers with mTORC1 activation and defective autophagy.
    J Hepatol. 2021 Oct 25. pii: S0168-8278(21)02151.
    >> Share

  257. LOGLIO A, Ferenci P, Uceda Renteria SC, Tham CYL, et al
    Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
    J Hepatol. 2021 Oct 23. pii: S0168-8278(21)02119.
    >> Share

  258. LAN T, Hu Y, Hu F, Li H, et al
    Hepatocyte glutathione S-transferase mu 2 prevents non-alcoholic steatohepatitis by suppressing ASK1 signaling.
    J Hepatol. 2021 Oct 14. pii: S0168-8278(21)02105.
    >> Share

  259. WHITFIELD JB, Schwantes-An TH, Darlay R, Aithal GP, et al
    A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers.
    J Hepatol. 2021 Oct 13. pii: S0168-8278(21)02111.
    >> Share

  260. QING J, Ren Y, Zhang Y, Yan M, et al
    Dopamine receptor D2 antagonization normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02097.
    >> Share

  261. SCHEINER B, Pomej K, Kirstein MM, Hucke F, et al
    Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.
    J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02100.
    >> Share

  262. SEN P, Qadri S, Luukkonen PK, Ragnarsdottir O, et al
    Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease.
    J Hepatol. 2021 Oct 7. pii: S0168-8278(21)02104.
    >> Share

  263. PINYOL R, Torrecilla S, Wang H, Montironi C, et al
    Corrigendum to 'Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis' [J Hepatol 75 (2021) 865-878].
    J Hepatol. 2021 Oct 6. pii: S0168-8278(21)02044.
    >> Share

  264. BEAUFRERE A, Caruso S, Calderaro J, Pote N, et al
    Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies.
    J Hepatol. 2021 Oct 5. pii: S0168-8278(21)02099.
    >> Share

  265. KIM HY, Lampertico P, Nam JY, Lee HC, et al
    An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02087.
    >> Share

  266. BAFFY G, Bosch J
    Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?
    J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02090.
    >> Share

  267. WONG F, Piano S, Angeli P
    Reply to: Correspondence on "Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure".
    J Hepatol. 2021;75:1010-1012.
    >> Share

  268. FENG MW, Hanley KL, Feng GS
    Androgen receptor, neovascularization and liver cancer metastasis.
    J Hepatol. 2021;75:768-769.
    >> Share

  269. LIN S, Agarwal B, Kumar R, Jalan R, et al
    Defining the prognosis of critically ill patients with alcohol-related liver disease.
    J Hepatol. 2021;75:986-987.
    >> Share

  270. FISCHER P, Stefanescu H, Hategan R, Procopet B, et al
    Bacterial infection-related acute-on-chronic liver failure: The standpoint matters!
    J Hepatol. 2021;75:1009-1010.
    >> Share

  271. FERNANDEZ-CHECA JC, Bagnaninchi P, Ye H, Sancho-Bru P, et al
    Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET].
    J Hepatol. 2021;75:935-959.
    >> Share

  272. CHEN X, Chen S, Pang J, Tang Y, et al
    Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?
    J Hepatol. 2021;75:987-989.
    >> Share

  273. LACKNER C, Stauber RE, Davies S, Denk H, et al
    Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease.
    J Hepatol. 2021;75:810-819.
    >> Share

  274. YOUNES R, Caviglia GP, Govaere O, Rosso C, et al
    Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:786-794.
    >> Share

  275. GOLABI P, Paik JM, AlQahtani S, Younossi Y, et al
    Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019.
    J Hepatol. 2021;75:795-809.
    >> Share

  276. SELVARAJ EA, Mozes FE, Jayaswal ANA, Zafarmand MH, et al
    Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    J Hepatol. 2021;75:770-785.
    >> Share

    September 2021
  277. GIABICANI M, Le Menestrel A, Roux O, Rautou PE, et al
    Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: a case control study from the prospective COVID-ICU database.
    J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02080.
    >> Share

  278. HSIEH J, Molusky MM, McCabe KM, Fotakis P, et al
    TTC39B destabilizes retinoblastoma protein promoting hepatic lipogenesis in a sex-specific fashion.
    J Hepatol. 2021 Sep 30. pii: S0168-8278(21)02083.
    >> Share

  279. GRONEBERG M, Hoenow S, Marggraff C, Fehling H, et al
    HIF-1alpha modulates sex-specific Th17/Treg responses during hepatic amoebiasis.
    J Hepatol. 2021 Sep 29. pii: S0168-8278(21)02082.
    >> Share

  280. D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
    Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
    >> Share

  281. CHOI WM, Yip TC, Lim YS, Wong GL, et al
    Methodological Challenges in Meta-Analysis to Assess the Risk of Hepatocellular Carcinoma Across Chronic Hepatitis B Treatments.
    J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02079.
    >> Share

  282. PATEL V, Lee S, McPhail M, Da Silva K, et al
    Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
    J Hepatol. 2021 Sep 24. pii: S0168-8278(21)02040.
    >> Share

  283. KIM HS, Yu X, Kramer J, Thrift AP, et al
    Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.
    J Hepatol. 2021 Sep 23. pii: S0168-8278(21)02039.
    >> Share

  284. ARTRU F, le Goffic C, Pageaux GP, Saliba F, et al
    Sarcopenia should be evaluated in patients with acute-on-chronic liver failure and candidates to liver transplantation.
    J Hepatol. 2021 Sep 15. pii: S0168-8278(21)02034.
    >> Share

  285. JUANOLA A, Graupera I, Elia C, Piano S, et al
    Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis.
    J Hepatol. 2021 Sep 13. pii: S0168-8278(21)02029.
    >> Share

  286. CHEN Q, Wang H, Li Z, Li F, et al
    Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription.
    J Hepatol. 2021 Sep 9. pii: S0168-8278(21)02025.
    >> Share

  287. DAI CY, Yeh ML, Yu ML
    An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously.
    J Hepatol. 2021 Sep 4. pii: S0168-8278(21)02021.
    >> Share

  288. VUPPALANCHI R, Caldwell SH, Pyrsopoulos N, deLemos AS, et al
    Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
    J Hepatol. 2021 Sep 3. pii: S0168-8278(21)02023.
    >> Share

  289. DING ZY, Li GX, Shu C, Yin P, et al
    Reply to: Comments on "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:742-744.
    >> Share

  290. LUO MS, Huang GJ
    Letter regarding "Association of liver abnormalities with in-hospital mortality in patients with COVID-19".
    J Hepatol. 2021;75:737-739.
    >> Share

  291. SINGH A, Premkumar M, Singh V
    Liver injury in COVID-19 - The culprit may not be COVID-19!
    J Hepatol. 2021;75:739-740.
    >> Share

  292. MCCONNELL MJ, Kawaguchi N, Kondo R, Sonzogni A, et al
    Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.
    J Hepatol. 2021;75:647-658.
    >> Share

  293. WANG Q, Bai W, Han G
    Freiburg index of post-TIPS survival: The first score for individual prediction and a complementary tool for risk stratification.
    J Hepatol. 2021;75:747-749.
    >> Share

  294. BETTINGER D, Thimme R, Schultheiss M
    Reply to: Correspondence on "Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival".
    J Hepatol. 2021;75:749-750.
    >> Share

  295. PAPATHEODORIDI M, Pinzani M, Tsochatzis E
    Reply to: "Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?"
    J Hepatol. 2021;75:752-753.
    >> Share

  296. PARK H, Yoon EL, Cho S, Nah EH, et al
    Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?
    J Hepatol. 2021;75:725-726.
    >> Share

  297. MA L, Craig AJ, Heinrich S
    Hypoxia is a key regulator in liver cancer progression.
    J Hepatol. 2021;75:736-737.
    >> Share

  298. KRAGLUND F, Gantzel RH, Jepsen P, Aagaard NK, et al
    External validation of the Freiburg index of post-TIPS survival.
    J Hepatol. 2021;75:746-747.
    >> Share

  299. GENESCA J, Abraldes JG, Bosch J
    Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?
    J Hepatol. 2021;75:750-752.
    >> Share


  300. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.
    J Hepatol. 2021;75:659-689.
    >> Share

  301. YOO T, Joo SK, Kim HJ, Kim HY, et al
    Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:514-523.
    >> Share

  302. CORRADINI E, Buzzetti E, Dongiovanni P, Scarlini S, et al
    Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD.
    J Hepatol. 2021;75:506-513.
    >> Share

    August 2021
  303. WANG H, Zhang S, Zhang Y, Jia J, et al
    TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
    J Hepatol. 2021 Aug 28. pii: S0168-8278(21)02016.
    >> Share

  304. DAI CY, Chuang WL, Yu ML
    A prospective study in predicting portal thrombosis in cirrhosis: Some Issues.
    J Hepatol. 2021 Aug 27. pii: S0168-8278(21)02010.
    >> Share

  305. RICKE J, Schinner R, Seidensticker M, Gasbarrini A, et al
    Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02003.
    >> Share

  306. THULUVATH PJ, Robarts P, Chauhan M
    Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
    J Hepatol. 2021 Aug 26. pii: S0168-8278(21)02002.
    >> Share

  307. BLOOM P, Tapper EB, Young VB, Lok AS, et al
    Microbiome Therapeutics for Hepatic Encephalopathy.
    J Hepatol. 2021 Aug 25. pii: S0168-8278(21)01998.
    >> Share

  308. WANG H, Zhang H, Wang Y, Brown ZJ, et al
    Regulatory T cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis.
    J Hepatol. 2021 Aug 4. pii: S0168-8278(21)01962.
    >> Share

  309. WANG J, Hou Z, Liu J, Gu Y, et al
    Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.
    J Hepatol. 2021;75:439-441.
    >> Share

  310. NACHIT M, Kwanten WJ, Thissen JP, Op De Beeck B, et al
    Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.
    J Hepatol. 2021;75:292-301.
    >> Share

  311. TAVABIE OD, Karvellas CJ, Salehi S, Speiser JL, et al
    A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure.
    J Hepatol. 2021;75:424-434.
    >> Share

  312. ASHBY K, Zhuang W, Gonzalez-Jimenez A, Alvarez-Alvarez I, et al
    Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI.
    J Hepatol. 2021;75:333-341.
    >> Share

  313. MARTINEZ J, Hernandez-Gea V, Rodriguez-de-Santiago E, Tellez L, et al
    Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis.
    J Hepatol. 2021;75:342-350.
    >> Share

  314. YANG Y, Sangwung P, Kondo R, Jung Y, et al
    Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease.
    J Hepatol. 2021;75:377-386.
    >> Share

    July 2021
  315. TORGERSEN J, Newcomb CW, Carbonari DM, Rentsch CT, et al
    Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01950.
    >> Share

  316. TURON F, Driever EG, Baiges A, Cerda E, et al
    Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors.
    J Hepatol. 2021 Jul 29. pii: S0168-8278(21)01946.
    >> Share

  317. CARPINO G, Cardinale V, Di Giamberardino A, Overi D, et al
    Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jul 27. pii: S0168-8278(21)01947.
    >> Share

  318. GALLE PR, Abou-Alfa G
    Decision making in systemic therapy of hepatocellular carcinoma: should we pay attention to disease etiology?
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01913.
    >> Share

  319. SCHULTALBERS M, Grote-Koska D, Cornberg M, Schmidt JJ, et al
    Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis.
    J Hepatol. 2021 Jul 23. pii: S0168-8278(21)01914.
    >> Share

  320. BRISSOT P, Loreal O
    Hemochromatoses.
    J Hepatol. 2021 Jul 11. pii: S0168-8278(21)00226.
    >> Share

  321. BRUIX J, Chan SL, Galle PR, Rimassa L, et al
    Systemic treatment of hepatocellular carcinoma. An EASL position paper.
    J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01903.
    >> Share

  322. VAQUERO J, Keitel V
    Deciphering FAK in intrahepatic cholangiocarcinoma: a novel therapeutic target?
    J Hepatol. 2021 Jul 9. pii: S0168-8278(21)01902.
    >> Share

  323. CLARIA J, Curto A, Moreau R, Colsch B, et al
    Untargeted lipidomics uncovers lipid signatures distinguishing severe versus moderate forms of acutely decompensated cirrhosis.
    J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01895.
    >> Share

  324. ZHU C, Boucheron N, Muller AC, Majek P, et al
    24-NorUrsodeoxycholic acid reshapes immunometabolism in CD8(+) T-cells and alleviates hepatic inflammation.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01886.
    >> Share

  325. BETTINGER D, Thimme R, Schultheiss M
    Reply: TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01891.
    >> Share

  326. SLADKY VC, Eichin F, Reiberger T, Villunger A, et al
    Polyploidy control in hepatic health and disease.
    J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01879.
    >> Share

  327. ALVARADO-TAPIAS E, Vilades D, Brujats A, Villanueva C, et al
    Reply letter to correspondence entitled: "Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?"
    J Hepatol. 2021 Jul 2. pii: S0168-8278(21)01846.
    >> Share

  328. VAN DER MERWE S, Chokshi S, Bernsmeier C, Albillos A, et al
    The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S82-S100.
    >> Share

  329. TREBICKA J, Macnaughtan J, Schnabl B, Shawcross DL, et al
    The microbiota in cirrhosis and its role in hepatic decompensation.
    J Hepatol. 2021;75 Suppl 1:S67-S81.
    >> Share

  330. ENGELMANN C, Claria J, Szabo G, Bosch J, et al
    Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.
    J Hepatol. 2021;75 Suppl 1:S49-S66.
    >> Share

  331. JEPSEN P, Younossi ZM
    The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.
    J Hepatol. 2021;75 Suppl 1:S3-S13.
    >> Share

  332. TANDON P, Montano-Loza AJ, Lai JC, Dasarathy S, et al
    Sarcopenia and frailty in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S147-S162.
    >> Share

  333. JALAN R, D'Amico G, Trebicka J, Moreau R, et al
    New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S14-S26.
    >> Share

  334. GARCIA-PAGAN JC, Francoz C, Montagnese S, Senzolo M, et al
    Management of the major complications of cirrhosis: Beyond guidelines.
    J Hepatol. 2021;75 Suppl 1:S135-S146.
    >> Share

  335. CARACENI P, Abraldes JG, Gines P, Newsome PN, et al
    The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.
    J Hepatol. 2021;75 Suppl 1:S118-S134.
    >> Share

  336. FERNANDEZ J, Piano S, Bartoletti M, Wey EQ, et al
    Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.
    J Hepatol. 2021;75 Suppl 1:S101-S117.
    >> Share

  337. JALAN R, Szabo G
    New concepts and perspectives in decompensated cirrhosis.
    J Hepatol. 2021;75 Suppl 1:S1-S2.
    >> Share

  338. KREMOSER C
    FXR agonists for NASH: How are they different and what difference do they make?
    J Hepatol. 2021;75:12-15.
    >> Share

  339. LIU Y, Xu N, Ji H
    Reply to: "Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice".
    J Hepatol. 2021;75:241-243.
    >> Share

  340. BOSCH J
    Reply to: "Achieving an effective pressure reduction after TIPS: The need for a new target".
    J Hepatol. 2021;75:248-249.
    >> Share

  341. STAUBER RE, Scharnagl H, Marsche G
    Reply to: "Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF".
    J Hepatol. 2021;75:245-246.
    >> Share

  342. SIMBRUNNER B, Costa D, Reiberger T
    Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease".
    J Hepatol. 2021;75:234-236.
    >> Share

  343. XU L, Wettschureck N, Bai Y, Yuan Z, et al
    Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice.
    J Hepatol. 2021;75:238-241.
    >> Share

  344. WEN X, Tong J, Yao M, Hu J, et al
    Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF.
    J Hepatol. 2021;75:243-245.
    >> Share

  345. WANG X, Luo X, Yang L
    Achieving an effective pressure reduction after TIPS: The need for a new target.
    J Hepatol. 2021;75:246-248.
    >> Share

  346. FERRARESE A, Plebani M, Frigo AC, Burra P, et al
    Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease.
    J Hepatol. 2021;75:232-234.
    >> Share

  347. BEUERS U
    EASL recognition award recipient 2021: Prof. Dieter Haussinger.
    J Hepatol. 2021;75:7-9.
    >> Share

  348. ROMERO-GOMEZ M
    EASL international recognition award recipient 2021: Prof. Dr. Nahum Mendez-Sanchez.
    J Hepatol. 2021;75:10-11.
    >> Share

  349. MENDEZ-SANCHEZ N, Diaz-Orozco L, Cordova-Gallardo J
    Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience.
    J Hepatol. 2021;75:221-222.
    >> Share

  350. PETERS L, Burkert S, Gruner B
    Parasites of the liver - epidemiology, diagnosis and clinical management in the European context.
    J Hepatol. 2021;75:202-218.
    >> Share

  351. SIMON J, Goikoetxea-Usandizaga N, Serrano-Macia M, Fernandez-Ramos D, et al
    Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH.
    J Hepatol. 2021;75:34-45.
    >> Share

  352. LIU C, Zhou B, Meng M, Zhao W, et al
    FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease.
    J Hepatol. 2021;75:150-162.
    >> Share

  353. STEPHENS C, Robles-Diaz M, Medina-Caliz I, Garcia-Cortes M, et al
    Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry.
    J Hepatol. 2021;75:86-97.
    >> Share

  354. GUSTOT T, Stadlbauer V, Laleman W, Alessandria C, et al
    Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events.
    J Hepatol. 2021;75 Suppl 1:S36-S48.
    >> Share

  355. MOREAU R, Gao B, Papp M, Banares R, et al
    Acute-on-chronic liver failure: A distinct clinical syndrome.
    J Hepatol. 2021;75 Suppl 1:S27-S35.
    >> Share

  356. BURRA P, Samuel D, Sundaram V, Duvoux C, et al
    Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation.
    J Hepatol. 2021;75 Suppl 1:S178-S190.
    >> Share

  357. BERNAL W, Karvellas C, Saliba F, Saner FH, et al
    Intensive care management of acute-on-chronic liver failure.
    J Hepatol. 2021;75 Suppl 1:S163-S177.
    >> Share

    June 2021
  358. MA L, Wang L, Khatib SA, Chang CW, et al
    Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 30. pii: S0168-8278(21)01848.
    >> Share

  359. VITHAYATHIL M, Bridegwater J, Khan SA
    Medical therapies for intra-hepatic cholangiocarcinoma.
    J Hepatol. 2021 Jun 29. pii: S0168-8278(21)00238.
    >> Share

  360. QUITT O, Luo S, Meyer M, Xie Z, et al
    T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
    J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00443.
    >> Share

  361. D'AMICO G, Bernardi M, Angeli P
    TOWARDS A NEW DEFINITION OF DECOMPENSATED CIRRHOSIS.
    J Hepatol. 2021 Jun 19. pii: S0168-8278(21)00438.
    >> Share

  362. BOU SALEH M, Louvet A, Ntandja-Wandji LC, Boleslawski E, et al
    Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis.
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00416.
    >> Share

  363. GEIDL-FLUECK B, Gerber PA
    Reply to Comments on "Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00418.
    >> Share

  364. SELLAU J, Groneberg M, Hoenow S, Lotter H, et al
    The underlying cellular immune pathology of Entamoeba histolytica-induced hepatic amoebiasis.
    J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00221.
    >> Share

  365. WU J, Li H, Xu Z, Ran L, et al
    Population-specific cut-off points of fatty liver index for the diagnosis of hepatic steatosis.
    J Hepatol. 2021 Jun 9. pii: S0168-8278(21)00413.
    >> Share

  366. CORPECHOT C
    Reply to: "Chronic fatigue should not be overlooked in primary biliary cholangitis".
    J Hepatol. 2021 Jun 6. pii: S0168-8278(21)00404.
    >> Share

  367. FLEMMING JA, Velez MP
    The ART of medicine: Counselling women with liver disease about assisted reproductive technology.
    J Hepatol. 2021;74:1283-1285.
    >> Share

  368. KUMAR R, Jalan R
    Reply to: "Failure to control variceal bleeding: Definition matters".
    J Hepatol. 2021;74:1492-1493.
    >> Share

  369. BAIGES A, Bureau C, Garcia-Pagan JC
    Failure to control variceal bleeding: Definition matters.
    J Hepatol. 2021;74:1491-1492.
    >> Share

  370. BERNAL W, McPhail MJ
    Acute liver failure.
    J Hepatol. 2021;74:1489-1490.
    >> Share

  371. GILGENKRANTZ H, Mallat A, Moreau R, Lotersztajn S, et al
    Targeting cell-intrinsic metabolism for antifibrotic therapy.
    J Hepatol. 2021;74:1442-1454.
    >> Share

  372. BRUIX J
    Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot.
    J Hepatol. 2021;74:1483-1488.
    >> Share

  373. BETTINGER D, Sturm L, Pfaff L, Hahn F, et al
    Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.
    J Hepatol. 2021;74:1362-1372.
    >> Share

  374. CADOUX M, Caruso S, Pham S, Gougelet A, et al
    Expression of NKG2D ligands is downregulated by beta-catenin signalling and associates with HCC aggressiveness.
    J Hepatol. 2021;74:1386-1397.
    >> Share

  375. WEI G, Cao J, Huang P, An P, et al
    Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4(-/-) mouse model of PFIC3.
    J Hepatol. 2021;74:1416-1428.
    >> Share

  376. ABDALLAH MA, Kuo YF, Asrani S, Wong RJ, et al
    Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
    J Hepatol. 2021;74:1355-1361.
    >> Share

    May 2021
  377. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
    Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
    J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
    >> Share

  378. RUDLER M, Savier E, Alioua I, Sultanik P, et al
    TIPS and liver transplantation should always be discussed together.
    J Hepatol. 2021 May 26. pii: S0168-8278(21)00347.
    >> Share

  379. BAUMERT TF
    "We can and should do better" - an interview with the 2020 Nobel prize laureates who revolutionized hepatology.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00312.
    >> Share

  380. CORNBERG M, Eberhardt CS
    Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.
    J Hepatol. 2021 May 25. pii: S0168-8278(21)00342.
    >> Share

  381. CORDELL HJ, Fryett JJ, Ueno K, Darlay R, et al
    An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs.
    J Hepatol. 2021 May 22. pii: S0168-8278(21)00334.
    >> Share

  382. WANG H, Wen B, Chen J
    "Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?" -Reply.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00335.
    >> Share

  383. NAN Y, An J, Bao J, Chen H, et al
    The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.
    J Hepatol. 2021 May 18. pii: S0168-8278(21)00332.
    >> Share

  384. ZHOU HC, Liu CX, Pan WD, Shang LR, et al
    Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma.
    J Hepatol. 2021 May 15. pii: S0168-8278(21)00331.
    >> Share

  385. PINYOL R, Torrecilla S, Wang H, Montironi C, et al
    Molecular characterization of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
    J Hepatol. 2021 May 13. pii: S0168-8278(21)00326.
    >> Share

  386. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Erratum to: "Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia" (J Hepatol 2021; 74: 428-441).
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00330.
    >> Share

  387. KUDO M, Matilla A, Santoro A, Melero I, et al
    CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
    J Hepatol. 2021 May 12. pii: S0168-8278(21)00313.
    >> Share

  388. ROMBAUT M, Boeckmans J, Rodrigues RM, van Grunsven LA, et al
    Direct reprogramming of somatic cells into induced hepatocytes: cracking the Enigma code.
    J Hepatol. 2021 May 11. pii: S0168-8278(21)00314.
    >> Share

  389. YEO YH, Hwang J, Jeong D, Dang N, et al
    Surveillance of patients with cirrhosis remains suboptimal in the United States.
    J Hepatol. 2021 May 6. pii: S0168-8278(21)00307.
    >> Share

  390. HYUN J, Al Abo M, Dutta RK, Oh SH, et al
    Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
    J Hepatol. 2021 May 5. pii: S0168-8278(21)00298.
    >> Share

  391. CABRE N, Luciano-Mateo F, Chapski DJ, Baiges-Gaya G, et al
    Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression.
    J Hepatol. 2021 May 4. pii: S0168-8278(21)00302.
    >> Share

  392. JOHNSON PJ
    In search of an evidence base for HCC surveillance: Purity or pragmatism?
    J Hepatol. 2021;74:1025-1027.
    >> Share

  393. ARROYO V, Fernandez J, Moreau R
    Reply to: "Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome".
    J Hepatol. 2021;74:1265-1267.
    >> Share

  394. COENRAAD MJ, Artru F
    Amino acids in acute-on-chronic liver failure: Another piece of the puzzle?
    J Hepatol. 2021;74:1015-1017.
    >> Share

  395. ESLAM M, George J
    MAFLD: Now is the time to capitalize on the momentum.
    J Hepatol. 2021;74:1262-1263.
    >> Share

  396. FOUAD Y, Gomaa A, Semida N, Ghany WA, et al
    Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists.
    J Hepatol. 2021;74:1254-1256.
    >> Share

  397. ALEM SA, Gaber Y, Abdalla M, Said E, et al
    Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback.
    J Hepatol. 2021;74:1261-1262.
    >> Share

  398. KASPER P, Martin A, Lang S, Demir M, et al
    Hypertension in NAFLD: An uncontrolled burden.
    J Hepatol. 2021;74:1258-1260.
    >> Share

  399. SPEARMAN CW, Desalegn H, Ocama P, Awuku YA, et al
    The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD.
    J Hepatol. 2021;74:1256-1258.
    >> Share

  400. ZHANG Y, Lu Z, Zeng W, Zhao J, et al
    Two sides of NNMT in alcoholic and non-alcoholic fatty liver development.
    J Hepatol. 2021;74:1250-1253.
    >> Share

  401. ZACCHERINI G, Aguilar F, Caraceni P, Claria J, et al
    Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF.
    J Hepatol. 2021;74:1117-1131.
    >> Share

  402. WANG T, Chen K, Yao W, Zheng R, et al
    Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance.
    J Hepatol. 2021;74:1038-1052.
    >> Share

    April 2021
  403. IZZY M, Lin G, Watt KD
    Non-selective beta blockers and mortality in decompensated Cirrhosis: Is Cirrhotic Cardiomyopathy the missing link?
    J Hepatol. 2021 Apr 28. pii: S0168-8278(21)00260.
    >> Share

  404. SENZOLO M, Garcia-Tsao G, Garcia-Pagan JC
    Current knowledge and management of portal vein thrombosis in cirrhosis.
    J Hepatol. 2021 Apr 27. pii: S0168-8278(21)00265.
    >> Share

  405. BETTINGER D, Kloeckner R, Boettler T, Thimme R, et al
    Reply: Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Apr 26. pii: S0168-8278(21)00264.
    >> Share

  406. VILLANUEVA C, Albillos A, Genesca J, Garcia-Pagan JC, et al
    Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.
    J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00257.
    >> Share

  407. BELLI LS, Duvoux C, Artzner T, Bernal W, et al
    Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: results of the ELITA/EF-CLIF collaborative study (ECLIS).
    J Hepatol. 2021 Apr 24. pii: S0168-8278(21)00261.
    >> Share

  408. GINES P
    Robert W Schrier, an influential observer from outside Hepatology (1936-2021).
    J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00180.
    >> Share

  409. TAPPER EB, Nikirk S, Parikh N, Zhao L, et al
    Falls are common, morbid, and predictable in patients with cirrhosis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00247.
    >> Share

  410. OOI GJ, Meikle PJ, Huynh K, Earnest A, et al
    Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.
    J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00248.
    >> Share

  411. TANAKA A, Hirohara J, Nakano T, Matsumoto K, et al
    Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
    J Hepatol. 2021 Apr 18. pii: S0168-8278(21)00245.
    >> Share

  412. GOLSE N, Vibert E, Vignon-Clementel IE
    Comments on: "A step forward to predict the risk of post-hepatectomy portal hypertension".
    J Hepatol. 2021 Apr 15. pii: S0168-8278(21)00242.
    >> Share

  413. SUNDARAM V
    Characterizing bacterial infections in acute-on-chronic liver failure among patients with cirrhosis from nonalcoholic steatohepatitis.
    J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00240.
    >> Share

  414. CRAMER T, Vaupel P
    Is tissue hypoxia the principle mechanism for immune evasion and malignant progression in Hepatocellular Carcinoma?
    J Hepatol. 2021 Apr 8. pii: S0168-8278(21)00228.
    >> Share

  415. PRINZ P
    Comments on "fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial".
    J Hepatol. 2021 Apr 5. pii: S0168-8278(21)00225.
    >> Share

  416. DESSEIN A
    Clinical utility of polygenic risk scores for predicting NAFLD disorders.
    J Hepatol. 2021;74:769-770.
    >> Share

  417. COSTA D, Simbrunner B, Reiberger T
    Reply to: "Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease".
    J Hepatol. 2021;74:1000-1001.
    >> Share

  418. HOBEIKA C, Fuks D
    Reply to: "Letter regarding Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2021;74:987-988.
    >> Share

  419. HEGARTY R, Singh S, Bansal S, Fitzpatrick E, et al
    NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.
    J Hepatol. 2021;74:991-992.
    >> Share

  420. ESLAM M, Ratziu V, George J
    Yet more evidence that MAFLD is more than a name change.
    J Hepatol. 2021;74:977-979.
    >> Share

  421. ESLAM M, George J
    MAFLD: A holistic view to redefining fatty liver disease.
    J Hepatol. 2021;74:983-985.
    >> Share

  422. ESLAM M, George J
    MAFLD: A game changer redefining fatty liver disease for adults and children.
    J Hepatol. 2021;74:992-994.
    >> Share

  423. AMPUERO J, Gallego-Duran R, Romero-Gomez M
    Reply to: "The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD".
    J Hepatol. 2021;74:971-972.
    >> Share

  424. ZHENG KI, Sun DQ, Jin Y, Zhu PW, et al
    Clinical utility of the MAFLD definition.
    J Hepatol. 2021;74:989-991.
    >> Share

  425. DEBNATH P, Rathi P
    Prognostic role of systemic inflammatory biomarkers in advanced chronic liver disease.
    J Hepatol. 2021;74:999-1000.
    >> Share

  426. MORENO C, Sheron N, Tiniakos D, Lackner C, et al
    "Dual aetiology fatty liver disease": A recently proposed term associated with potential pitfalls.
    J Hepatol. 2021;74:979-982.
    >> Share

  427. BAFFY G
    Is the name 'NAFLD' too big to fail? Let's keep it for 'nutrition-associated fatty liver disease'.
    J Hepatol. 2021;74:988.
    >> Share

  428. XIA M, Zeng H, Wang S, Tang H, et al
    Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR-based lipoprotein profiling.
    J Hepatol. 2021;74:974-977.
    >> Share

  429. LIU M, Sun L, Mao Y
    The predictive value of significant fibrosis for metabolic disturbances in patients with NAFLD.
    J Hepatol. 2021;74:970-971.
    >> Share

  430. SINGH SP, Anirvan P, Reddy KR, Conjeevaram HS, et al
    Non-alcoholic fatty liver disease: Not time for an obituary just yet!
    J Hepatol. 2021;74:972-974.
    >> Share

  431. PONIACHIK J, Roblero JP, Urzua A, Cattaneo M, et al
    A new definition for non-alcoholic fatty liver disease.
    J Hepatol. 2021;74:982-983.
    >> Share

  432. RUSSOLILLO N, Aldrighetti L, Guglielmi A, Giuliante F, et al
    Correspondence on "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2021;74:985-986.
    >> Share

  433. RIMASSA L, Personeni N, Czauderna C, Foerster F, et al
    Systemic treatment of HCC in special populations.
    J Hepatol. 2021;74:931-943.
    >> Share

  434. COSTA D, Simbrunner B, Jachs M, Hartl L, et al
    Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.
    J Hepatol. 2021;74:819-828.
    >> Share

    March 2021
  435. POCH T, Krause J, Casar C, Liwinski T, et al
    Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00219.
    >> Share

  436. MONTAGNESE S, Lauridsen M, Vilstrup H, Zarantonello L, et al
    A pilot study of Golexanolone, a new GABA-A receptor modulating steroid antagonist, in patients with covert hepatic encephalopathy.
    J Hepatol. 2021 Mar 24. pii: S0168-8278(21)00184.
    >> Share

  437. BASHO K, Bettinger D, Boettler T
    Reply to "IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?"
    J Hepatol. 2021 Mar 23. pii: S0168-8278(21)00187.
    >> Share

  438. POSE E, Torrents A, Reverter E, Perez-Campuzano V, et al
    A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00175.
    >> Share

  439. HARRISON SA, Gawrieh S, Roberts K, Lisanti CJ, et al
    Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00176.
    >> Share

  440. AN YA, Chen S, Deng Y, Wang ZV, et al
    The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00174.
    >> Share

  441. LI J, Zhu X, Zhang M, Zhang Y, et al
    Limb expression 1-like (LIX1L) protein promotes cholestatic liver injury by regulating bile acid metabolism.
    J Hepatol. 2021 Mar 18. pii: S0168-8278(21)00177.
    >> Share

  442. PUTERA M, Teh KB, Kumar R, Wong YJ, et al
    Small esophageal varices in compensated cirrhosis patients: to treat or not to treat?
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00167.
    >> Share

  443. STOCKHOFF L, Schneider H, Tergast TL, Cornberg M, et al
    Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?
    J Hepatol. 2021 Mar 11. pii: S0168-8278(21)00168.
    >> Share

  444. LIAO SH, Chen CL, Hsu CY, Chien KL, et al
    Long-term Effectiveness of Population-wide Multifaceted Interventions for Hepatocellular Carcinoma in Taiwan.
    J Hepatol. 2021 Mar 6. pii: S0168-8278(21)00163.
    >> Share

  445. GEIDL-FLUECK B, Hochuli M, Nemeth A, Eberl A, et al
    Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial.
    J Hepatol. 2021 Mar 5. pii: S0168-8278(21)00161.
    >> Share

  446. ANSTEE QM, Darlay R, Cockell S, Meroni M, et al
    Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort" (J Hepatol [2020] 505-515).
    J Hepatol. 2021 Mar 4. pii: S0168-8278(21)00103.
    >> Share

  447. JAMIALAHMADI O, Bianco C, Pelusi S, Romeo S, et al
    Population attributable risk of cirrhosis and hepatocellular carcinoma due to genetic predisposition to fatty liver disease.
    J Hepatol. 2021 Mar 4. pii: S0168-8278(21)00164.
    >> Share

  448. WANG J, Liu D, Qi X
    A step forward to predict the risk of post-hepatectomy portal hypertension.
    J Hepatol. 2021 Mar 2. pii: S0168-8278(21)00159.
    >> Share

  449. MEIJNIKMAN AS, Bruin S, Groen AK, Nieuwdorp M, et al
    Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD.
    J Hepatol. 2021;74:748-749.
    >> Share

  450. MARJOT T, Moon AM, Cook JA, Abd-Elsalam S, et al
    Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
    J Hepatol. 2021;74:567-577.
    >> Share

  451. LUJAMBIO A, Maina F
    Turning up our understanding of liver cancer by a notch.
    J Hepatol. 2021;74:502-504.
    >> Share

  452. JOYE R, Lador F, Aggoun Y, Farhat N, et al
    Outcome of paediatric portopulmonary hypertension in the modern management era: A case report of 6 patients.
    J Hepatol. 2021;74:742-747.
    >> Share

  453. HEINRICH S, Craig AJ, Ma L, Heinrich B, et al
    Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis.
    J Hepatol. 2021;74:700-715.
    >> Share

  454. MOZZANEGA B
    Ulipristal acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya.
    J Hepatol. 2021;74:750-751.
    >> Share

  455. CHAND D, Mohr F, McMillan H, Tukov FF, et al
    Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
    J Hepatol. 2021;74:560-566.
    >> Share

  456. MUTANEN A, Lohi J, Merras-Salmio L, Koivusalo A, et al
    Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure.
    J Hepatol. 2021;74:593-602.
    >> Share

    February 2021
  457. SHAHINI E, Ahmed F
    Chronic fatigue should not be overlooked in primary biliary cholangitis.
    J Hepatol. 2021 Feb 25. pii: S0168-8278(21)00154.
    >> Share

  458. GUDD CL, Au L, Triantafyllou E, Shum B, et al
    Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis.
    J Hepatol. 2021 Feb 22. pii: S0168-8278(21)00108.
    >> Share

  459. KEIDING S, Frisch K, Hofmann AF
    Reply to: "Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion".
    J Hepatol. 2021 Feb 20. pii: S0168-8278(21)00114.
    >> Share

  460. MALLET V
    Intravenous ketamine and progressive cholangiopathy in Covid-19 patients.
    J Hepatol. 2021 Feb 19. pii: S0168-8278(21)00107.
    >> Share

  461. HE Y, Feng D, Hwang S, Mackowiak B, et al
    Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IkappaBzeta target genes in hepatocytes.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00104.
    >> Share

  462. BARTOLI A, Gitto S, Sighinolfi P, Cursaro C, et al
    PRIMARY BILIARY CHOLANGITIS ASSOCIATED WITH SARS-COV2 INFECTION.
    J Hepatol. 2021 Feb 18. pii: S0168-8278(21)00106.
    >> Share

  463. FABRIS L, Cadamuro M, Fouassier L
    Illuminate TWEAK/Fn14 pathway in intrahepatic cholangiocarcinoma: Another brick in the wall of tumor niche.
    J Hepatol. 2021 Feb 11. pii: S0168-8278(20)33892.
    >> Share

  464. HARRISON SA, Bashir MR, Lee KJ, Shim-Lopez J, et al
    A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    J Hepatol. 2021 Feb 10. pii: S0168-8278(21)00099.
    >> Share

  465. LIANG B, Zhou Y, Qian M, Xu M, et al
    TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00095.
    >> Share

  466. LIEBE R, Esposito I, Bock HH, Dahl SV, et al
    Diagnosis and management of secondary causes of steatohepatitis.
    J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00096.
    >> Share

  467. CORNBERG M, Buti M, Eberhardt CS, Grossi PA, et al
    EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
    J Hepatol. 2021 Feb 6. pii: S0168-8278(21)00081.
    >> Share

  468. TERGAST TL, Schultalbers M, Wedemeyer H, Cornberg M, et al
    IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?
    J Hepatol. 2021 Feb 3. pii: S0168-8278(21)00089.
    >> Share

  469. GUPTA P, Soundararajan R, Patel A, Kumar-M P, et al
    Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis.
    J Hepatol. 2021 Feb 3. pii: S0168-8278(21)00091.
    >> Share

  470. BEAUFRERE A, Calderaro J, Paradis V
    Combined hepatocellular-cholangiocarcinoma: An update.
    J Hepatol. 2021 Feb 2. pii: S0168-8278(21)00084.
    >> Share

  471. MUSHTAQ K, Khan MU, Iqbal F, Alsoub DH, et al
    NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues.
    J Hepatol. 2021;74:482-484.
    >> Share

  472. JI D, Cheng G, Lau G
    Reply to: "NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues".
    J Hepatol. 2021;74:484-485.
    >> Share

  473. RIPOLL C, Zipprich A
    Open or closed window: That is the question.
    J Hepatol. 2021;74:485-486.
    >> Share

  474. ANAND A, Kumar R, Shalimar
    PREDICTing acute-on-chronic liver failure in patients with acute decompensation.
    J Hepatol. 2021;74:478-479.
    >> Share

  475. HERNAEZ R, Kanwal F
    Reply to: "The role of the model for end-stage liver disease sodium score and joint models for 90-day mortality prediction in in patients with acute-on-chronic liver failure".
    J Hepatol. 2021;74:477.
    >> Share

  476. GOUDSMIT BFJ, Tushuizen ME, Putter H, Braat AE, et al
    The role of the model for end-stage liver disease-sodium score and joint models for 90-day mortality prediction in patients with acute-on-chronic liver failure.
    J Hepatol. 2021;74:475-476.
    >> Share

  477. MANCO R, Itzkovitz S
    Liver zonation.
    J Hepatol. 2021;74:466-468.
    >> Share

  478. SAWATZKI M, Guller U, Gusewell S, Husarik DB, et al
    Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases.
    J Hepatol. 2021;74:419-427.
    >> Share

  479. WINKLER M, Staniczek T, Kurschner SW, Schmid CD, et al
    Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling.
    J Hepatol. 2021;74:380-393.
    >> Share

  480. WONG F, Piano S, Singh V, Bartoletti M, et al
    Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure.
    J Hepatol. 2021;74:330-339.
    >> Share

    January 2021
  481. SONG Q, Wang J, Griffiths A, Song Z, et al
    Reply to: "NNMT aggravates hepatic steatosis but alleviates liver injury in alcoholic liver disease" and "Two sides of NNMT in alcoholic and nonalcoholic fatty liver development".
    J Hepatol. 2021 Jan 30. pii: S0168-8278(21)00083.
    >> Share

  482. GWAG T, Meng Z, Sui Y, Helsley RN, et al
    Erratum to: Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis [J Hepatol (2019); 70 (5): 930-940].
    J Hepatol. 2021 Jan 29. pii: S0168-8278(21)00003.
    >> Share

  483. WU X, Poulsen KL, Sanz-Garcia C, Huang E, et al
    Erratum to: "MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcoholic-associated fatty liver and steatohepatitis (J Hepatol 2020; 73: 616-627)".
    J Hepatol. 2021 Jan 29. pii: S0168-8278(21)00014.
    >> Share

  484. CONDE DE LA ROSA L, Garcia-Ruiz C, Vallejo C, Baulies A, et al
    STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway.
    J Hepatol. 2021 Jan 27. pii: S0168-8278(21)00040.
    >> Share

  485. JAVITT NB
    Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion.
    J Hepatol. 2021 Jan 25. pii: S0168-8278(21)00044.
    >> Share

  486. SCHATTENBERG JM, Pares A, Kowdley KV, Heneghan MA, et al
    A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
    J Hepatol. 2021 Jan 20. pii: S0168-8278(21)00022.
    >> Share

  487. SAMUEL D
    Systemic inflammation and liver cirrhosis complications: driving or secondary event? How to square the circle?
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00001.
    >> Share

  488. LONG J, Bian J, Zhao H
    Polygenic risk score: a promising predictor for hepatocellular carcinoma in the population with nonalcoholic fatty liver disease.
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00019.
    >> Share

  489. RACHWAN RJ, Kutkut I, Timsina LR, Bou Chaaya RG, et al
    CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates.
    J Hepatol. 2021 Jan 18. pii: S0168-8278(21)00016.
    >> Share

  490. JEPSEN P, West J
    We need stronger evidence for (or against) hepatocellular carcinoma surveillance.
    J Hepatol. 2021 Jan 16. pii: S0168-8278(21)00020.
    >> Share

  491. RAHIM MN, Theocharidou E, Yen Lau KG, Ahmed R, et al
    Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.
    J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00005.
    >> Share

  492. GOLDBERG D, Mantero A, Newcomb C, Delgado C, et al
    Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score.
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00004.
    >> Share

  493. FAN R, Yin X, Hou J
    Reply to "External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs".
    J Hepatol. 2021 Jan 13. pii: S0168-8278(21)00011.
    >> Share

  494. BURTON AR, Pallett LJ
    IL-2 leaves its mark in cirrhosis.
    J Hepatol. 2021 Jan 6. pii: S0168-8278(20)33833.
    >> Share

  495. FORLANO R, Mullish BH, Maurice JB, Thursz MR, et al
    NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials.
    J Hepatol. 2021;74:241-242.
    >> Share

  496. WU Y, Kumar R, Huang J, Wang M, et al
    FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD).
    J Hepatol. 2021;74:247-248.
    >> Share

  497. NAYAGAM JS, Strautnieks S, Joshi D, Thompson RJ, et al
    Challenges in understanding the consequences of variants in ABCB4 gene.
    J Hepatol. 2021;74:242-243.
    >> Share

  498. TSOCHATZIS EA, Srivastava A, Rosenberg W
    Reply to: "FIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)".
    J Hepatol. 2021;74:248-249.
    >> Share

  499. SAVALE L, Sitbon O
    Reply to: "Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?"
    J Hepatol. 2021;74:238-239.
    >> Share

  500. KOLHE K, Tripathi DM, Kaur S
    Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?
    J Hepatol. 2021;74:237-238.
    >> Share

  501. STATTERMAYER AF, Ferenci P, Trauner M
    Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene".
    J Hepatol. 2021;74:244-245.
    >> Share

  502. COZMESCU AC, Counsell J, Gissen P
    Gene therapies targeting the liver.
    J Hepatol. 2021;74:235-236.
    >> Share

  503. BOSCH J
    Small diameter shunts should lead to safe expansion of the use of TIPS.
    J Hepatol. 2021;74:230-234.
    >> Share

  504. DWYER BJ, Macmillan MT, Brennan PN, Forbes SJ, et al
    Cell therapy for advanced liver diseases: Repair or rebuild.
    J Hepatol. 2021;74:185-199.
    >> Share

  505. TEO K, Abeysekera KWM, Adams L, Aigner E, et al
    rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis.
    J Hepatol. 2021;74:20-30.
    >> Share

    December 2020
  506. FERRUSQUIA-ACOSTA J, Turco L, Hernandez-Gea V
    Reply to: "Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications".
    J Hepatol. 2020 Dec 29. pii: S0168-8278(20)33837.
    >> Share

  507. SHARMA S, Anand A, Saraya A
    Underestimation of portal pressures by wedge hepatic venous pressures in patients with non-alcoholic steatohepatitis related cirrhosis- Possibilities and implications.
    J Hepatol. 2020 Dec 22. pii: S0168-8278(20)33736.
    >> Share

  508. WANG H, Chen J
    Reply to: "Prospective validation of Baveno VI criteria in virally supressed HBV cirrhosis - more evidence is needed".
    J Hepatol. 2020 Dec 19. pii: S0168-8278(20)33839.
    >> Share

  509. SHARMA S, Agarwal S
    Prospective validation of Baveno VI criteria in virally supressed HBV cirrhosis - more evidence is needed.
    J Hepatol. 2020 Dec 19. pii: S0168-8278(20)33687.
    >> Share

  510. LISMAN T, Luyendyk JP
    Response to "The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis".
    J Hepatol. 2020 Dec 18. pii: S0168-8278(20)33890.
    >> Share

  511. CALVARUSO V, Craxi A
    Reply to letters to the Editor on manuscript "Hepatic benefits of HCV cure". JHEPAT-D-20-01349R1.
    J Hepatol. 2020 Dec 17. pii: S0168-8278(20)33888.
    >> Share

  512. SARKAR M, Grab J, Irani RA
    Reply to: "Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?"
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33806.
    >> Share

  513. NINGARHARI M, Caruso S, Hirsch TZ, Bayard Q, et al
    Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
    J Hepatol. 2020 Dec 15. pii: S0168-8278(20)33846.
    >> Share

  514. AVANCENA ALV, Miller N, Uttal SE, Hutton DW, et al
    Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.
    J Hepatol. 2020 Dec 13. pii: S0168-8278(20)33841.
    >> Share

  515. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Corrigendum to "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules" [J Hepatol (2019) 874-884].
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33773.
    >> Share

  516. PHILLIPS J, Senaratne S
    Intrahepatic cholestasis of pregnancy: An under recognised complication of maternal NAFLD?
    J Hepatol. 2020 Dec 11. pii: S0168-8278(20)33694.
    >> Share

  517. BRESSON-HADNI S, Montange D, Richou C, Brumpt E, et al
    Tobacco, cannabis, and liquorice: Hidden players altering albendazole metabolism in patients with hepatic alveolar echinococcosis.
    J Hepatol. 2020 Dec 10. pii: S0168-8278(20)33749.
    >> Share

  518. ARROYO V, Angeli P, Moreau R, Jalan R, et al
    The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis.
    J Hepatol. 2020 Dec 7. pii: S0168-8278(20)33836.
    >> Share

  519. BOYER-DIAZ Z, Aristu-Zabalza P, Andres-Rozas M, Robert C, et al
    Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33832.
    >> Share

  520. TREBICKA J, Fernandez J, Arroyo V
    Reply to: Correspondence on 'The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology'.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33765.
    >> Share

  521. WEIL D, Thevenot T, Saas P, Di Martino V, et al
    Relevance of platelet-derived microvesicles in cirrhosis: The debate remains open.
    J Hepatol. 2020 Dec 2. pii: S0168-8278(20)33745.
    >> Share

  522. BAUMERT TF
    The Nobel Prize in Medicine 2020 for the Discovery of Hepatitis C Virus: Transforming Hepatology.
    J Hepatol. 2020;73:1303-1305.
    >> Share

  523. VASAVAN T, Deepak S, Jayawardane IA, Lucchini M, et al
    Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33825.
    >> Share

  524. DIGGS LP, Ruf B, Ma C, Heinrich B, et al
    CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Dec 1. pii: S0168-8278(20)33824.
    >> Share

  525. MARTINEZ-CHANTAR ML, Foti M
    NFATc4: New hub in NASH development.
    J Hepatol. 2020;73:1313-1315.
    >> Share

  526. TANWAR S, Srivastava A, Rosenberg W
    Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:1580-1581.
    >> Share

  527. HERNAEZ R, Liu Y, Kanwal F
    Reply to: "Model for end-stage liver disease-sodium in acute-on-chronic liver failure".
    J Hepatol. 2020;73:1579-1580.
    >> Share

  528. MOSCA A, Panera N, Maggiore G, Alisi A, et al
    From pregnant women to infants: Non-alcoholic fatty liver disease is a poor inheritance.
    J Hepatol. 2020;73:1590-1592.
    >> Share

  529. GOH BKP
    Letter regarding "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers".
    J Hepatol. 2020;73:1576.
    >> Share

  530. HOBEIKA C, Fuks D
    Reply to: 'Letter regarding "Benchmark performance of laparoscopic left lateral sectionectomy and right hepatectomy in expert centers"'.
    J Hepatol. 2020;73:1577-1578.
    >> Share

  531. VALI Y, Anstee QM, Bossuyt PM
    Reply to: "Errors in modeling misrepresent the utility of the enhanced liver fibrosis test in the management of non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:1582-1583.
    >> Share

  532. MAK LY, Yuen MF, Seto WK
    Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement".
    J Hepatol. 2020;73:1573-1574.
    >> Share

  533. MANKA P, Canbay A, Bechmann LP
    Model for end-stage liver disease-sodium in acute-on-chronic liver failure.
    J Hepatol. 2020;73:1578-1579.
    >> Share

  534. ESLAM M, George J
    Reply to: correspondence regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement": Bringing evidence to the NAFLD-MAFLD debate.
    J Hepatol. 2020;73:1575.
    >> Share

  535. RATZIU V, Rinella M, Beuers U, Loomba R, et al
    The times they are a-changin' (for NAFLD as well).
    J Hepatol. 2020;73:1307-1309.
    >> Share

  536. JALAN R, Arroyo V
    Organ allocation for patients with acute-on-chronic liver failure: Time to look beyond MELD-sodium?
    J Hepatol. 2020;73:1316-1318.
    >> Share

    November 2020
  537. KUPRIYANOVA Y, Zaharia OP, Bobrov P, Karusheva Y, et al
    Early changes in hepatic energy metabolism and lipid content in recent-onset type 1 and 2 diabetes mellitus.
    J Hepatol. 2020 Nov 28. pii: S0168-8278(20)33817.
    >> Share

  538. BIANCO C, Jamialahmadi O, Pelusi S, Baselli G, et al
    Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
    J Hepatol. 2020 Nov 25. pii: S0168-8278(20)33811.
    >> Share

  539. SU F, Weiss NS, Beste LA, Moon AM, et al
    Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B.
    J Hepatol. 2020 Nov 24. pii: S0168-8278(20)33807.
    >> Share

  540. DING Q, Ma Y, Lai S, Dou X, et al
    NNMT aggravates hepatic steatosis, but alleviates liver injury in alcoholic liver disease.
    J Hepatol. 2020 Nov 24. pii: S0168-8278(20)33812.
    >> Share

  541. KELLUM JA, Nadim MK
    Acute kidney disease and cirrhosis.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33756.
    >> Share

  542. KRASSENBURG LAP, Maan R, Ramji A, Manns MP, et al
    Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    J Hepatol. 2020 Nov 23. pii: S0168-8278(20)33805.
    >> Share

  543. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
    PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.
    J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33772.
    >> Share

  544. CHEN H, Cai J, Wang J, Qiu Y, et al
    Targeting Nestin(+) hepatic stellate cells ameliorates liver fibrosis by facilitating TbetaRI degradation.
    J Hepatol. 2020 Nov 17. pii: S0168-8278(20)33769.
    >> Share

  545. HUANG YH, Zhang CZ, Huang QS, Yeong J, et al
    Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33763.
    >> Share

  546. GOLSE N, Joly F, Combari P, Lewin M, et al
    Predicting the risk of post-hepatectomy portal hypertension using a digital twin: a clinical proof of concept.
    J Hepatol. 2020 Nov 16. pii: S0168-8278(20)33761.
    >> Share

  547. ARECHEDERRA M, Bazai SK, Abdouni A, Sequera C, et al
    ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.
    J Hepatol. 2020 Nov 13. pii: S0168-8278(20)33758.
    >> Share

  548. MEHTA N, Dodge JL, Roberts JP, Yao FY, et al
    A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    J Hepatol. 2020 Nov 11. pii: S0168-8278(20)33750.
    >> Share

  549. KUCUKOGLU O, Sowa JP, Mazzolini GD, Syn WK, et al
    Hepatokines and adipokines in NASH-related hepatocellular carcinoma.
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33746.
    >> Share

  550. ZANETTO A, Simioni P, Russo FP
    Hepatic benefits of HCV cure: don't forget coagulation!
    J Hepatol. 2020 Nov 5. pii: S0168-8278(20)33747.
    >> Share

  551. ANTOINE DJ, Jenkins RE, Dear JW, Williams DP, et al
    Retraction notice to "Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity": J Hepatol 56(2012)1070-1079.
    J Hepatol. 2020;73:1297.
    >> Share

  552. JOTHIMANI D, Venugopal R, Abedin MF, Kaliamoorthy I, et al
    COVID-19 and the liver.
    J Hepatol. 2020;73:1231-1240.
    >> Share

  553. MEHTANI R, Roy A, Verma N, Premkumar M, et al
    Beta-blockers in refractory ascites - is it truly the end of the road?
    J Hepatol. 2020;73:1290-1291.
    >> Share

  554. TELLEZ L, Ibanez-Samaniego L, Banares R, Albillos A, et al
    Reply to: "Beta-blockers in refractory ascites - is it truly the end of the road?"
    J Hepatol. 2020;73:1291-1292.
    >> Share

  555. UNFRIED JP, Fortes P
    SMIM30, a tiny protein with a big role in liver cancer.
    J Hepatol. 2020;73:1010-1012.
    >> Share

  556. HUANG J, Kumar R, Wang M, Zhu Y, et al
    MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?
    J Hepatol. 2020;73:1265-1267.
    >> Share

  557. ESLAM M, George J
    Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice.
    J Hepatol. 2020;73:1268-1269.
    >> Share

  558. VAN HEES S, Muyindike W, Erem G, Ocama P, et al
    Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda.
    J Hepatol. 2020;73:1271-1273.
    >> Share

  559. SINGAL AG, Lampertico P, Nahon P
    Reply to: "Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda".
    J Hepatol. 2020;73:1273-1274.
    >> Share

    October 2020
  560. WANG J, Wang Y, Chu Y, Li Z, et al
    Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma.
    J Hepatol. 2020 Oct 30. pii: S0168-8278(20)33739.
    >> Share

  561. CHAN SL
    Hyperprogression in hepatocellular carcinoma: Illusion or reality?
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33669.
    >> Share

  562. TRAMPERT DC, van de Graaf SFJ, Jongejan A, Oude Elferink RPJ, et al
    Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33690.
    >> Share

  563. MOHS A, Otto T, Schneider KM, Peltzer M, et al
    Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
    J Hepatol. 2020 Oct 24. pii: S0168-8278(20)33695.
    >> Share

  564. BASHO K, Zoldan K, Schultheiss M, Bettinger D, et al
    IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33692.
    >> Share

  565. SHIHA G, Mikhail N, Soliman R
    External validation of aMAP risk score in Chronic hepatitis C genotype 4 patients with liver cirrhosis who achieved SVR following DAAs.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33688.
    >> Share

  566. DEPAIRE M, Larrue H, Rudler M, Nault JC, et al
    Futility criteria for preemptive TIPS in patients with cirrhosis and variceal bleeding are still missing in most severe patients!
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33689.
    >> Share

  567. MOGA L, Laroyenne A, Larrue H, Bureau C, et al
    Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis.
    J Hepatol. 2020 Oct 23. pii: S0168-8278(20)33691.
    >> Share

  568. ROSE CF, Amodio P, Bajaj JS, Dhiman RK, et al
    Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy.
    J Hepatol. 2020 Oct 21. pii: S0168-8278(20)30466.
    >> Share

  569. FERRUSQUIA-ACOSTA J, Bassegoda O, Turco L, Reverter E, et al
    Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33683.
    >> Share

  570. CARBONE M, Ronca V, Invernizzi P
    Reply to: "A spotlight on natural killer cells in primary biliary cholangitis".
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33663.
    >> Share

  571. HYDES T, Khakoo SI
    A spotlight on natural killer cells in primary biliary cholangitis.
    J Hepatol. 2020 Oct 14. pii: S0168-8278(20)33595.
    >> Share

  572. CAI SY, Yu D, Soroka CJ, Wang J, et al
    Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33680.
    >> Share

  573. WANG H, Wen B, Chang X, Wu Q, et al
    Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.
    J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33678.
    >> Share

  574. MORIKAWA R, Nakamoto N, Amiya T, Chu PS, et al
    Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33677.
    >> Share

  575. FRENETTE C, Kayali Z, Mena E, Mantry PS, et al
    Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33673.
    >> Share

  576. ZHU C, Ho YJ, Salomao MA, Dapito DH, et al
    Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    J Hepatol. 2020 Oct 7. pii: S0168-8278(20)33676.
    >> Share

  577. KIM TH, Koh YH, Kim BH, Kim MJ, et al
    Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase trial.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33670.
    >> Share

  578. LIU C, Zha Z, Zhou C, Chen Y, et al
    Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33674.
    >> Share

  579. FONDEVILA MF, Mercado-Gomez M, Rodriguez A, Gonzalez-Rellan MJ, et al
    Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points.
    J Hepatol. 2020 Oct 5. pii: S0168-8278(20)33671.
    >> Share

  580. MAGAZ M, Alvarez-Larran A, Colomer D, Lopez M, et al
    Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis".
    J Hepatol. 2020 Oct 2. pii: S0168-8278(20)33621.
    >> Share

  581. WANG Y, Lu F, Zhao J
    Reply to: Correspondence relating to "SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19".
    J Hepatol. 2020;73:996-998.
    >> Share

  582. MEHAL WZ
    From mice to humans: Unravelling the genetic levers of NASH.
    J Hepatol. 2020;73:749-751.
    >> Share

  583. O'BRIEN A, Karvellas CJ
    Acute-on-chronic liver failure: The challenge of PREDICTing who and when.
    J Hepatol. 2020;73:755-756.
    >> Share

  584. HUO TI, Ho SY, Ko CC
    Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers.
    J Hepatol. 2020;73:972-973.
    >> Share

  585. SCHWARZKOPF KM, Eberle L, Uschner FE, Klein S, et al
    Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?
    J Hepatol. 2020;73:980-982.
    >> Share

  586. TREBICKA J, Gu W, Garcia-Pagan JC, Bosch J, et al
    Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?": pTIPS for variceal bleeding in ACLF patients: when and why?
    J Hepatol. 2020;73:977-979.
    >> Share

  587. XIANG X, Hwang S, Gao B
    Reply to: "Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?": The search for an optimal mouse model.
    J Hepatol. 2020;73:982-984.
    >> Share

  588. ELHENCE A, Kumar R, Shalimar
    Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?
    J Hepatol. 2020;73:976-977.
    >> Share

  589. KIM N, Seong J
    Reply to: "Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers".
    J Hepatol. 2020;73:973-974.
    >> Share

    September 2020
  590. WEN Z, Feng Y, Yan X
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Sep 29. pii: S0168-8278(20)30491.
    >> Share

  591. GRONBAEK H, Gantzel RH, Laursen TL, Kazankov K, et al
    Macrophage markers and innate immunity in cirrhosis.
    J Hepatol. 2020 Sep 26. pii: S0168-8278(20)30486.
    >> Share

  592. PAPATHEODORIDIS G, Sypsa V, Lampertico P
    Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B".
    J Hepatol. 2020 Sep 25. pii: S0168-8278(20)33615.
    >> Share

  593. SCHUMACHER N, Yan K, Gandrass M, Muller M, et al
    Cell-autonomous hepatocyte-specific GP130 signalling is sufficient to trigger a robust innate immune response in mice.
    J Hepatol. 2020 Sep 25. pii: S0168-8278(20)33664.
    >> Share

  594. TREMBLAY D, Mascarenhas J, Schiano T, Naymagon L, et al
    Comment on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis".
    J Hepatol. 2020 Sep 24. pii: S0168-8278(20)30531.
    >> Share

  595. ZHENG KI, Liu C, Li J, Zhao L, et al
    Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.
    J Hepatol. 2020 Sep 21. pii: S0168-8278(20)30447.
    >> Share

  596. ARGIRION I, Mahale P, Pfeiffer RM, Koshiol J, et al
    Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma.
    J Hepatol. 2020 Sep 19. pii: S0168-8278(20)30465.
    >> Share

  597. PARISINOS CA, Wilman HR, Thomas EL, Kelly M, et al
    Corrigendum to: "Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis" [J Hepatol (2020) 241-251].
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33603.
    >> Share

  598. SECKLER F, Doussot A, Colpart P, Turco C, et al
    Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)30366.
    >> Share

  599. HIRSCHFIELD GM, Beuers U, Kupcinskas L, Ott P, et al
    A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33623.
    >> Share

  600. LEE-LAW PY, Olaizola P, Caballero-Camino FJ, Izquierdo-Sanchez L, et al
    Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
    J Hepatol. 2020 Sep 17. pii: S0168-8278(20)33622.
    >> Share

  601. SCHATTENBERG JM, Straub BK
    On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis.
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)30475.
    >> Share

  602. ALFAIATE D, Clement S, Goossens N, Negro F, et al
    Reply to: "Cirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinoma".
    J Hepatol. 2020 Sep 12. pii: S0168-8278(20)30543.
    >> Share

  603. KIM N, Cheng J, Jung I, Liang J, et al
    Corrigendum to: "Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma" [J Hepatol (2020) 121-129].
    J Hepatol. 2020 Sep 10. pii: S0168-8278(20)33602.
    >> Share

  604. TONON M, Rosi S, Gambino CG, Piano S, et al
    Natural history of acute kidney disease in patients with cirrhosis.
    J Hepatol. 2020 Sep 9. pii: S0168-8278(20)33612.
    >> Share

  605. CHAN LK, Wai-Hung Ho D, Kam CS, Yung-Tuen Chiu E, et al
    RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma.
    J Hepatol. 2020 Sep 9. pii: S0168-8278(20)33610.
    >> Share

  606. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Corrigendum to: "Portopulmonary hypertension in the current era of pulmonary hypertension management" [J Hepatol (2020);73:130-139].
    J Hepatol. 2020 Sep 7. pii: S0168-8278(20)33591.
    >> Share

  607. FABRIS L, Andersen JB, Fouassier L
    Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment.
    J Hepatol. 2020 Sep 5. pii: S0168-8278(20)30471.
    >> Share

  608. MERLI M
    Nutrition in cirrhosis: Dos and Don'ts.
    J Hepatol. 2020 Sep 2. pii: S0168-8278(20)30474.
    >> Share

  609. SERPER M, Shaked A, Olthoff KM, Hoteit M, et al
    A local response to COVID-19 for advanced liver disease: Current model of care, challenges and opportunities.
    J Hepatol. 2020;73:708-709.
    >> Share

  610. VALENTI L, Jamialahmadi O, Romeo S
    Lack of genetic evidence that fatty liver disease predisposes to COVID-19.
    J Hepatol. 2020;73:709-711.
    >> Share

  611. DI GIORGIO A, Nicastro E, Speziani C, De Giorgio M, et al
    Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy.
    J Hepatol. 2020;73:702-705.
    >> Share

  612. JI D, Xu J, Qin E, Zhang D, et al
    Reply to: 'No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease'.
    J Hepatol. 2020;73:718-719.
    >> Share

  613. BIQUARD L, Valla D, Rautou PE
    No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.
    J Hepatol. 2020;73:717-718.
    >> Share

  614. RICKE J, Sangro B, Malfertheiner P, Seidensticker M, et al
    Reply to: "Toxicity and dosimetry in SORAMIC study".
    J Hepatol. 2020;73:735-736.
    >> Share

  615. REINDERS M, Braat A, Lam M
    Toxicity and dosimetry in SORAMIC study.
    J Hepatol. 2020;73:734-735.
    >> Share

  616. DYSON JK, Jones DEJ
    UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
    J Hepatol. 2020;73:499-501.
    >> Share

  617. PAISANT A, Vilgrain V, Aube C
    Reply to: "Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents".
    J Hepatol. 2020;73:716-717.
    >> Share

  618. CHOI SH, Kim SY, Lim YS
    Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents.
    J Hepatol. 2020;73:714-715.
    >> Share

  619. ILIC I, Milovanovic T
    The risk-benefit assessment of liver biopsy in times of non-invasive screening for liver fibrosis.
    J Hepatol. 2020;73:701-702.
    >> Share

  620. GUIU B
    Stereotactic body radiation therapy vs. radiofrequency ablation in HCC: comparing noncomparable data.
    J Hepatol. 2020;73:727-728.
    >> Share

  621. JI D, Zhang D, Lau G
    Reply to: 'NAFLD or comorbidities, that is the question'.
    J Hepatol. 2020;73:724-725.
    >> Share

  622. PONZIANI FR, Gasbarrini A, Pompili M
    NAFLD or comorbidities, that is the question.
    J Hepatol. 2020;73:723.
    >> Share

    August 2020
  623. CHARETTE JH, Burak KW, Coffin CS, Congly SE, et al
    Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma.
    J Hepatol. 2020 Aug 31. pii: S0168-8278(20)30458.
    >> Share

  624. GENESCA J
    Reply to: "Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma".
    J Hepatol. 2020 Aug 24. pii: S0168-8278(20)30484.
    >> Share

  625. CARACENI P, Tufoni M, Zaccherini G, Riggio O, et al
    On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites.
    J Hepatol. 2020 Aug 24. pii: S0168-8278(20)33551.
    >> Share

  626. XU Z, Li H, Tian S, Wu J, et al
    Blood biomarkers for the diagnosis of hepatic steatosis in metabolic dysfunction-associated fatty liver disease.
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30371.
    >> Share

  627. SERENARI M, Ravaioli F, Cucchetti A, Kim SU, et al
    Reply to: "Response to A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Aug 21. pii: S0168-8278(20)30442.
    >> Share

  628. YOSHIZUMI T, Itoh S, Shimokawa M, Inokuchi S, et al
    Simultaneous splenectomy improves outcomes after adult living donor liver transplantation.
    J Hepatol. 2020 Aug 19. pii: S0168-8278(20)30547.
    >> Share

  629. FAN L, Lai R, Ma N, Dong Y, et al
    miR-552-3p modulates transcriptional activities of FXR and LXR to ameliorate hepatic glycolipid metabolism disorder.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30541.
    >> Share

  630. RHEE H, Cho ES, Nahm JH, Jang M, et al
    Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30544.
    >> Share

  631. LINE PD, Dueland S
    Liver transplantation for secondary liver tumors: the difficult balance between survival and recurrence.
    J Hepatol. 2020 Aug 17. pii: S0168-8278(20)30539.
    >> Share

  632. KIM CG, Kim C, Yoon SE, Kim KH, et al
    Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    J Hepatol. 2020 Aug 15. pii: S0168-8278(20)30540.
    >> Share

  633. MANNING C, Alam SM
    Response to "A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Aug 14. pii: S0168-8278(20)30380.
    >> Share

  634. SOLA E, Pose E, Campion D, Piano S, et al
    ENDPOINTS AND DESIGN OF CLINICAL TRIALS IN PATIENTS WITH DECOMPENSATED CIRRHOSIS: POSITION PAPER OF THE LIVERHOPE CONSORTIUM.
    J Hepatol. 2020 Aug 14. pii: S0168-8278(20)30536.
    >> Share

  635. CALVARUSO V, Craxi A
    Hepatic benefits of HCV cure.
    J Hepatol. 2020 Aug 7. pii: S0168-8278(20)30530.
    >> Share

  636. IAVARONE M, D'Ambrosio R, Lampertico P
    Authors' reply on HIGH RATES OF 30-DAY MORTALITY IN PATIENTS WITH CIRRHOSIS AND COVID-19.
    J Hepatol. 2020 Aug 6. pii: S0168-8278(20)30524.
    >> Share

  637. CALVARUSO V, Bruix J
    Towards personalized screening for hepatocellular carcinoma: still not there.
    J Hepatol. 2020 Aug 5. pii: S0168-8278(20)30405.
    >> Share

  638. GAUL S, Leszczynska A, Alegre F, Kaufmann B, et al
    Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.
    J Hepatol. 2020 Aug 4. pii: S0168-8278(20)30522.
    >> Share

  639. JI D, Qin E, Xu J, Zhang D, et al
    Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.
    J Hepatol. 2020;73:451-453.
    >> Share

  640. MERAT SJ, Bru C, van de Berg D, Molenkamp R, et al
    Erratum to: 'Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance' (J Hepatol 2019; 71(1): 14-24).
    J Hepatol. 2020 Aug 1. pii: S0168-8278(20)30455.
    >> Share

  641. PRAKTIKNJO M, Torner J, Simon-Talero M, Gu W, et al
    Reply to: "Definition of SPSS: we need to speak the same language": Computer-assisted image processing for better quantification.
    J Hepatol. 2020;73:464-465.
    >> Share

  642. NICOARA-FARCAU O, Wang X, Luo X
    Definition of SPSS: we need to speak the same language.
    J Hepatol. 2020;73:463-464.
    >> Share

    July 2020
  643. KOMOLL RM, Hu Q, Olarewaju O, von Dohlen L, et al
    MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma.
    J Hepatol. 2020 Jul 30. pii: S0168-8278(20)30492.
    >> Share

  644. LUO YD, Fang L, Yu HQ, Zhang J, et al
    p53 haploinsufficiency and increased mTOR signaling define a subset of aggressive hepatocellular carcinoma.
    J Hepatol. 2020 Jul 29. pii: S0168-8278(20)30489.
    >> Share

  645. KJAERGAARD K, Frisch K, Sorensen M, Munk OL, et al
    Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30481.
    >> Share

  646. DU M, Wang X, Yuan L, Liu B, et al
    Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice.
    J Hepatol. 2020 Jul 24. pii: S0168-8278(20)30482.
    >> Share

  647. SANGRO B, Melero I, Wadhawan S, Finn RS, et al
    Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
    J Hepatol. 2020 Jul 22. pii: S0168-8278(20)30479.
    >> Share

  648. FAN R, Papatheodoridis G, Sun J, Innes H, et al
    aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30478.
    >> Share

  649. LOHSE AW, Sebode M, Jorgensen MH, Ytting H, et al
    Second-line and Third-line therapy for Autoimmune Hepatitis A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group.
    J Hepatol. 2020 Jul 21. pii: S0168-8278(20)30470.
    >> Share

  650. SERENARI M, Ravaioli F, Cucchetti A, Kim SU, et al
    Reply to: "Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma".
    J Hepatol. 2020 Jul 20. pii: S0168-8278(20)30388.
    >> Share

  651. XU G, Xiao Y, Jin B, Sang X, et al
    Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma.
    J Hepatol. 2020 Jul 20. pii: S0168-8278(20)30343.
    >> Share

  652. TAJES SR, Pocurull A, Castillo J, Casanova G, et al
    Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions in the near future.
    J Hepatol. 2020 Jul 19. pii: S0168-8278(20)30472.
    >> Share

  653. SONG Y, An O, Ren X, Man Chan TH, et al
    RNA editing mediates the functional switch of COPA in a novel mechanism of hepatocarcinogenesis.
    J Hepatol. 2020 Jul 18. pii: S0168-8278(20)30476.
    >> Share

  654. ZHANG X, Fan L, Wu J, Xu H, et al
    Erratum to: "Macrophage p38 alpha promotes nutritional steatohepatitis through M1 polarization (J Hepatol 2019; 71(1):163-174)".
    J Hepatol. 2020 Jul 17. pii: S0168-8278(20)30390.
    >> Share

  655. VERNA EC, Akushevich L, Vainorius M, Fried MW, et al
    Reply to: "HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?"
    J Hepatol. 2020 Jul 15. pii: S0168-8278(20)30386.
    >> Share

  656. MAGAZ M, Alvarez-Larran A, Colomer D, Lopez-Guerra M, et al
    Next generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30456.
    >> Share

  657. SABOO K, Shamsaddini A, Iyer MV, Hu C, et al
    Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30457.
    >> Share

  658. MCPHAIL MJW, Coen M
    Metabolomics to discriminate between acute decompensation and acute-on-chronic liver failure in cirrhosis.
    J Hepatol. 2020 Jul 14. pii: S0168-8278(20)30183.
    >> Share

  659. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
    The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology (120/120).
    J Hepatol. 2020 Jul 10. pii: S0168-8278(20)30384.
    >> Share

  660. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    Erratum to: "Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17-25).
    J Hepatol. 2020 Jul 9. pii: S0168-8278(20)30389.
    >> Share

  661. MOREAU R, Aguilar F, Arroyo V
    Reply to: "Metabolomics to discriminate between acute decompensation and acute-on-chronic liver failure in cirrhosis".
    J Hepatol. 2020 Jul 8. pii: S0168-8278(20)30340.
    >> Share

  662. MEUNIER L, Pageaux GP, Coilly A
    HCV treatment in cirrhotic patients: Should we use a different approach for patients with a liver transplant perspective?
    J Hepatol. 2020 Jul 8. pii: S0168-8278(20)30345.
    >> Share

  663. DEEB M, Karlsen TH, Hirschfield GM
    The 6 C's of Primary Sclerosing Cholangitis.
    J Hepatol. 2020 Jul 7. pii: S0168-8278(20)30436.
    >> Share

  664. RINELLA ME, Noureddin M
    STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus.
    J Hepatol. 2020;73:9-11.
    >> Share

  665. LAZARUS JV, Cortez-Pinto H, Anstee QM
    Reply to: "Caveats for the implementation of global strategies against non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:221-222.
    >> Share

  666. SHAH S, Dhami-Shah H, Kamble S, Shukla A, et al
    FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:216-217.
    >> Share

  667. LEUNG M, Piao C, Sarkar S
    NAFLD referral patterns in a large US academic center.
    J Hepatol. 2020;73:218-219.
    >> Share

  668. TSOCHATZIS EA, Srivastava A, Rosenberg W
    Reply to: "FIB-4 cut off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease".
    J Hepatol. 2020;73:217-218.
    >> Share

  669. MENDEZ-SANCHEZ N, Valencia-Rodriguez A
    Caveats for the implementation of global strategies against non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:220.
    >> Share

  670. ZOU ZY, Fan JG
    Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease.
    J Hepatol. 2020;73:214-216.
    >> Share

    June 2020
  671. AUDUREAU E, Carrat F, Layese R, Cagnot C, et al
    Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.
    J Hepatol. 2020 Jun 29. pii: S0168-8278(20)30394.
    >> Share

  672. DONG P, Wang X, Liu L, Tang W, et al
    Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
    J Hepatol. 2020 Jun 28. pii: S0168-8278(20)30400.
    >> Share

  673. RUART M, Chavarria L, Camprecios G, Suarez-Herrera N, et al
    Corrigendum to: "Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury" [J Hepatol (2019) 458-469].
    J Hepatol. 2020 Jun 27. pii: S0168-8278(20)30354.
    >> Share

  674. LAMPL S, Janas MK, Donakonda S, Brugger M, et al
    Reduced mitochondrial resilience enables non-canonical induction of apoptosis after TNF receptor signaling in virus-infected hepatocytes.
    J Hepatol. 2020 Jun 26. pii: S0168-8278(20)30398.
    >> Share

  675. HAMON A, Piquet-Pellorce C, Dimanche-Boitrel MT, Samson M, et al
    Intrahepatocytic necroptosis is dispensable for hepatocyte death in murine immune-mediated hepatitis.
    J Hepatol. 2020 Jun 23. pii: S0168-8278(20)30308.
    >> Share

  676. FRAGA M, Moradpour D, Artru F, Romailler E, et al
    Hepatocellular Type II Fibrinogen Inclusions in a Patient with Severe COVID-19 and Hepatitis.
    J Hepatol. 2020 Jun 22. pii: S0168-8278(20)30393.
    >> Share

  677. BASSEGODA O, Sola E, Gines P
    Reply to: "Transition of AKI to CKD in cirrhosis - effect of baseline eGFR and unanswered questions".
    J Hepatol. 2020 Jun 21. pii: S0168-8278(20)30287.
    >> Share

  678. GAO F, Huang ZM
    The impact of COVID-19 on the clinical outcome of patients with cirrhosis deserves more attention and research.
    J Hepatol. 2020 Jun 20. pii: S0168-8278(20)30397.
    >> Share

  679. MEDHAT MA, El Kassas M
    Letter regarding [High rates of 30-day mortality in patients with cirrhosis and COVID-19].
    J Hepatol. 2020 Jun 20. pii: S0168-8278(20)30396.
    >> Share

  680. KUMAR R, Kerbert AJC, Sheikh MF, Roth N, et al
    Determinants of mortality in patients with cirrhosis and uncontrolled variceal bleeding.
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30381.
    >> Share

  681. BABU RO, Hang Lui VC, Chen Y, Wan Yiu RS, et al
    Beta-amyloid deposition around hepatic bile ducts is a novel pathobiological and diagnostic feature of biliary atresia.
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30383.
    >> Share

  682. COLNOT S, Lechel A
    Maternal obesity: A severe risk factor in hepatocarcinogenesis?
    J Hepatol. 2020 Jun 16. pii: S0168-8278(20)30385.
    >> Share

  683. PAPATHEODORIDIS GV, Dalekos GN, Idilman R, Sypsa V, et al
    Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
    J Hepatol. 2020 Jun 15. pii: S0168-8278(20)30382.
    >> Share

  684. SINGH I, De A, Singh V
    Transition of AKI to CKD in cirrhosis - effect of baseline eGFR and unanswered questions.
    J Hepatol. 2020 Jun 12. pii: S0168-8278(20)30184.
    >> Share

  685. RAI RP, Liu Y, Iyer SS, Liu S, et al
    Blocking integrin alpha4beta7-mediated CD4 T cell recruitment to the intestine and liver protects mice from western diet-induced non-alcoholic steatohepatitis.
    J Hepatol. 2020 Jun 12. pii: S0168-8278(20)30375.
    >> Share

  686. LENS S, Baiges A, Alvarado E, LLop E, et al
    Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
    J Hepatol. 2020 Jun 11. pii: S0168-8278(20)30368.
    >> Share

  687. IAVARONE M, D'Ambrosio R, Soria A, Triolo M, et al
    High rates of 30-day mortality in patients with cirrhosis and COVID-19.
    J Hepatol. 2020 Jun 8. pii: S0168-8278(20)30365.
    >> Share

  688. JEPSEN P, Kraglund F, West J, Villadsen GE, et al
    Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis.
    J Hepatol. 2020 Jun 5. pii: S0168-8278(20)30363.
    >> Share

  689. ZHANG M, Yang H, Wan L, Wang Z, et al
    Single cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma.
    J Hepatol. 2020 Jun 4. pii: S0168-8278(20)30360.
    >> Share

  690. SHIHA G
    External validation of non-invasive predictors of hepatocellular carcinoma in patients with HCV-related advanced chronic liver disease after oral antivirals.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30196.
    >> Share

  691. MAK LY, Wan-Hin Hui R, Fung J, Liu F, et al
    Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30361.
    >> Share

  692. MAK LY, Ka-Ho Wong D, Pollicino T, Raimondo G, et al
    Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance.
    J Hepatol. 2020 Jun 3. pii: S0168-8278(20)30357.
    >> Share

  693. GENESCA J
    Reply to: "Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?" and "External validation of noninvasive predictors of hepatocellular carcinoma in patie
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30237.
    >> Share

  694. NABATCHIKOVA E, Abdurakhmanov D, Rozina T, Nikulkina E, et al
    Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?
    J Hepatol. 2020 Jun 1. pii: S0168-8278(20)30197.
    >> Share

  695. EDELINE J, Garin E
    Streamlining TARE or personalizing SIRT? Different philosophies to treat different HCCs with Yttrium-90....
    J Hepatol. 2020;72:1046-1048.
    >> Share

  696. HARMS MH, van Buuren HR, van der Meer AJ
    Reply to: "Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience".
    J Hepatol. 2020;72:1211-1212.
    >> Share

  697. CORPECHOT C, Rousseau A, Chazouilleres O
    Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience.
    J Hepatol. 2020;72:1210-1211.
    >> Share

  698. KHORUTS A, Bajaj JS
    Reply to: " 'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation": Intestinal microbiota transplantation: Naming a new paradigm.
    J Hepatol. 2020;72:1213-1214.
    >> Share

  699. PHILIPS CA, Ahamed R, Rajesh S, Augustine P, et al
    'You know my name, but not my story' - Deciding on an accurate nomenclature for faecal microbiota transplantation.
    J Hepatol. 2020;72:1212-1213.
    >> Share

    May 2020
  700. DE SMET V, Verhulst S, van Grunsven LA
    Single cell RNA sequencing analysis did not predict hepatocyte infection by SARS-CoV-2.
    J Hepatol. 2020 May 27. pii: S0168-8278(20)30349.
    >> Share

  701. LUUKKONEN PK, Juuti A, Sammalkorpi H, Penttila AK, et al
    MARC1 variant rs2642438 increases hepatic phosphatidylcholines and decreases severity of non-alcoholic fatty liver disease in humans.
    J Hepatol. 2020 May 26. pii: S0168-8278(20)30234.
    >> Share

  702. KIM N, Seong J
    Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"
    J Hepatol. 2020 May 25. pii: S0168-8278(20)30229.
    >> Share

  703. CHEW CA, Iyer SG, Chieh Kow AW, Madhavan K, et al
    An international multicentre study of protocols for liver transplantation during a pandemic: A case for quadripartite equipoise.
    J Hepatol. 2020 May 23. pii: S0168-8278(20)30342.
    >> Share

  704. TELLEZ L, Ibanez-Samaniego L, Perez Del Villar C, Yotti R, et al
    Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites.
    J Hepatol. 2020 May 21. pii: S0168-8278(20)30303.
    >> Share

  705. MOON AM, Webb GJ, Aloman C, Armstrong MJ, et al
    High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry.
    J Hepatol. 2020 May 20. pii: S0168-8278(20)30305.
    >> Share

  706. CHAN HL, Wong VW, Yip TC, Wong GL, et al
    Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page".
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30273.
    >> Share

  707. RIOU J, Canivet CM, Boursier J
    Reply to: "Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward".
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30233.
    >> Share

  708. LUCIFORA J, Michelet M, Rivoire M, Protzer U, et al
    Two-dimensional-cultures of primary human hepatocytes allow efficient HBV infection: Old tricks still work!
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30204.
    >> Share

  709. SONNEVELD MJ, Brouwer WP, de Man RA
    Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page?
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30231.
    >> Share

  710. GULFO J, Rotondo F, de Leon CGA, Cornide-Petronio ME, et al
    FGF15 improves outcomes after brain dead donor liver transplantation with steatotic and non-steatotic grafts in rats.
    J Hepatol. 2020 May 15. pii: S0168-8278(20)30299.
    >> Share

  711. LI W
    Accurate diagnosis of NAFLD-related hepatic fibrosis with non-invasive methods: A comment for moving forward.
    J Hepatol. 2020 May 13. pii: S0168-8278(20)30179.
    >> Share

  712. KUMAR A
    Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?
    J Hepatol. 2020 May 11. pii: S0168-8278(20)30175.
    >> Share

  713. PENG ZP, Jiang ZZ, Guo HF, Zhou MM, et al
    Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma.
    J Hepatol. 2020 May 11. pii: S0168-8278(20)30296.
    >> Share

  714. WANG Y, Liu S, Liu H, Li W, et al
    SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.
    J Hepatol. 2020 May 10. pii: S0168-8278(20)30294.
    >> Share

  715. WANG S, Friedman SL
    Hepatic fibrosis: A convergent response to liver injury that is reversible.
    J Hepatol. 2020 May 8. pii: S0168-8278(20)30170.
    >> Share

  716. GAO J, Wei B, de Assuncao TM, Liu Z, et al
    Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis.
    J Hepatol. 2020 May 7. pii: S0168-8278(20)30290.
    >> Share

  717. DESAI AP, Knapp SM, Orman ES, Ghabril MS, et al
    Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis - a US population-based study.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30289.
    >> Share

  718. MEYER T
    Stereotactic body radiotherapy for hepatocellular carcinoma - still searching for a role.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30232.
    >> Share

  719. DAI Z, Ott M, Sharma AD
    Equal opportunity offer for all hepatocytes.
    J Hepatol. 2020 May 6. pii: S0168-8278(20)30200.
    >> Share

  720. SCHWERBEL K, Kamitz A, Krahmer N, Hallahan N, et al
    Immunity-related GTPase induces lipophagy to prevent excess hepatic lipid accumulation.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30275.
    >> Share

  721. BATES J, Vijayakumar A, Ghoshal S, Marchand B, et al
    Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30281.
    >> Share

  722. STATTERMAYER AF, Halilbasic E, Wrba F, Ferenci P, et al
    Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults.
    J Hepatol. 2020 May 3. pii: S0168-8278(20)30280.
    >> Share

  723. ABE H, Schuppan D
    beta-arrestin: Dr Jekyll and Mr Hyde in NASH and fibrosis.
    J Hepatol. 2020;72:813-815.
    >> Share

    April 2020
  724. SERENARI M, Han KH, Ravaioli F, Kim SU, et al
    A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma.
    J Hepatol. 2020 Apr 30. pii: S0168-8278(20)30276.
    >> Share

  725. LEFERE S, Puengel T, Hundertmark J, Penners C, et al
    Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.
    J Hepatol. 2020 Apr 29. pii: S0168-8278(20)30269.
    >> Share

  726. HIRSCH TZ, Negulescu A, Gupta B, Caruso S, et al
    Corrigendum to: "BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA" [J Hepatol (2020) 1-13].
    J Hepatol. 2020 Apr 29. pii: S0168-8278(20)30214.
    >> Share

  727. MAZUMDER NR, Celaj S, Atiemo K, Daud A, et al
    Liver-related mortality is similar among men and women with cirrhosis.
    J Hepatol. 2020 Apr 25. pii: S0168-8278(20)30235.
    >> Share

  728. FORREST E
    Alcohol-related liver disease results in significant long-term mortality irrespective of the presence of steatohepatitis.
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30117.
    >> Share

  729. DEGRE D, Stauber RE, Deltenre P, Lackner C, et al
    Reply to: "Alcohol-related liver disease results in significant long-term mortality irrespective of the presence of steatohepatitis".
    J Hepatol. 2020 Apr 20. pii: S0168-8278(20)30199.
    >> Share

  730. OKINA Y, Sato-Matsubara M, Matsubara T, Daikoku A, et al
    TGF-beta-driven reduction of cytoglobin leads to oxidative DNA damage in stellate cells during non-alcoholic steatohepatitis.
    J Hepatol. 2020 Apr 17. pii: S0168-8278(20)30228.
    >> Share

  731. TAPPER EB, Asrani SK
    COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30217.
    >> Share

  732. TAPIAS EA, Ardevol A, Garcia-Guix M, Montanes R, et al
    Short-term hemodynamic effects of beta-blockers influence survival of patients with decompensated cirrhosis.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30211.
    >> Share

  733. ANSTEE QM, Darlay R, Cockell S, Meroni M, et al
    Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort.
    J Hepatol. 2020 Apr 13. pii: S0168-8278(20)30213.
    >> Share

  734. LOPEZ-VICARIO C, Checa A, Urdangarin A, Aguilar F, et al
    Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis.
    J Hepatol. 2020 Apr 12. pii: S0168-8278(20)30208.
    >> Share

  735. CORPECHOT C, Chazouilleres O, Belnou P, Montano-Loza AJ, et al
    Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
    J Hepatol. 2020 Apr 7. pii: S0168-8278(20)30205.
    >> Share

  736. PARISINOS CA, Wilman HR, Thomas EL, Kelly M, et al
    Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis.
    J Hepatol. 2020 Apr 2. pii: S0168-8278(20)30194.
    >> Share

  737. CHOUDHARY NS, Saraf N, Saigal S, Soin AS, et al
    Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues.
    J Hepatol. 2020 Apr 2. pii: S0168-8278(20)30016.
    >> Share

  738. LEE HA, Kim BK, Kim SU
    Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy.
    J Hepatol. 2020 Apr 1. pii: S0168-8278(20)30121.
    >> Share

  739. GANNE-CARRIE N, Piscaglia F
    Non-enhanced MRI surveillance for HCC: A new tool for all, none or selected patients at risk?
    J Hepatol. 2020;72:607-609.
    >> Share

  740. ENGELMANN C, Mehta G, Tacke F
    Regeneration in acute-on-chronic liver failure - the phantom lost its camouflage.
    J Hepatol. 2020;72:610-612.
    >> Share

    March 2020
  741. VERNA EC, Morelli G, Terrault NA, Lok AS, et al
    DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30193.
    >> Share

  742. SANGIOVANNI A, Alimenti E, Gattai R, Filomia R, et al
    Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    J Hepatol. 2020 Mar 31. pii: S0168-8278(20)30192.
    >> Share

  743. LAI JC, Dodge JL, Kappus MR, Dunn MA, et al
    Changes in frailty are associated with waitlist mortality in patients with cirrhosis.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30191.
    >> Share

  744. BERNSMEIER C, van der Merwe S, Perianin A
    The innate immune cells in cirrhosis.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30189.
    >> Share

  745. CARRILLO-REIXACH J, Torrens L, Simon-Coma M, Royo L, et al
    Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.
    J Hepatol. 2020 Mar 30. pii: S0168-8278(20)30187.
    >> Share

  746. NEWSOME PN, Palmer M, Freilich B, Sheikh MY, et al
    Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
    J Hepatol. 2020 Mar 28. pii: S0168-8278(20)30186.
    >> Share

  747. PAPATHEODORIDIS GV, Lampertico P
    Reply to: "Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy".
    J Hepatol. 2020 Mar 27. pii: S0168-8278(20)30173.
    >> Share

  748. PARK HJ, Jang HY, Kim SY
    Reply to: "Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues".
    J Hepatol. 2020 Mar 26. pii: S0168-8278(20)30162.
    >> Share

  749. KHAN SA, Clements O, Kim JU, Eliahoo J, et al
    Reply to: 'Letter regarding [Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis]'.
    J Hepatol. 2020 Mar 23. pii: S0168-8278(20)30128.
    >> Share

  750. CUCCHETTI A, Serenari M, Sposito C, Di Sandro S, et al
    Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
    J Hepatol. 2020 Mar 19. pii: S0168-8278(20)30177.
    >> Share

  751. KOWDLEY KV, Vuppalanchi R, Levy C, Floreani A, et al
    A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
    J Hepatol. 2020 Mar 9. pii: S0168-8278(20)30160.
    >> Share

  752. HARRISON SA, Wai-Sun Wong V, Okanoue T, Bzowej N, et al
    Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials.
    J Hepatol. 2020 Mar 5. pii: S0168-8278(20)30126.
    >> Share

  753. SAVALE L, Guimas M, Ebstein N, Fertin M, et al
    Portopulmonary hypertension in the current era of pulmonary hypertension management.
    J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30119.
    >> Share

  754. WONG VW
    Predicting NASH response with liver fat: Are we back to square one?
    J Hepatol. 2020;72:386-388.
    >> Share

    February 2020
  755. ARFIANTI A, Pok S, Barn V, Haigh WG, et al
    Exercise retards hepatocarcinogenesis in obese mice independently of weight control.
    J Hepatol. 2020 Feb 20. pii: S0168-8278(20)30104.
    >> Share

  756. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
    Genotype correlates with the natural history of severe bile salt export pump deficiency.
    J Hepatol. 2020 Feb 19. pii: S0168-8278(20)30105.
    >> Share

  757. MULLER M, Bird TG, Nault JC
    The landscape of gene mutations in cirrhosis and hepatocellular carcinoma.
    J Hepatol. 2020 Feb 7. pii: S0168-8278(20)30060.
    >> Share

    January 2020
  758. BAJAJ JS, Khoruts A
    Microbiota changes and Intestinal Microbiota Transplantation in Liver Diseases and Cirrhosis.
    J Hepatol. 2020 Jan 28. pii: S0168-8278(20)30058.
    >> Share

  759. PRAKTIKNJO M, Simon-Talero M, Romer J, Roccarina D, et al
    Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis.
    J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30012.
    >> Share

  760. BASSEGODA O, Huelin P, Ariza X, Sole C, et al
    DEVELOPMENT OF CHRONIC KIDNEY DISEASE AFTER ACUTE KIDNEY INJURY IN PATIENTS WITH CIRRHOSIS IS COMMON AND IMPAIRS CLINICAL OUTCOMES.
    J Hepatol. 2020 Jan 14. pii: S0168-8278(20)30011.
    >> Share

    December 2019
  761. PAISANT A, Vilgrain V, Riou J, Oberti F, et al
    Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30725.
    >> Share

  762. GARCIA-TSAO G, Bosch J, Kayali Z, Harrison SA, et al
    Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension.
    J Hepatol. 2019 Dec 20. pii: S0168-8278(19)30724.
    >> Share

  763. SHE S, Wu X, Zheng D, Pei X, et al
    PSMP/MSMP promotes hepatic fibrosis through CCR2 and represents a novel therapeutic target.
    J Hepatol. 2019 Dec 5. pii: S0168-8278(19)30654.
    >> Share

    November 2019
  764. CHIEW AL, James LP, Isbister GK, Pickering JW, et al
    Early Acetaminophen-Protein Adducts Predict Hepatotoxicity Following Overdose.
    J Hepatol. 2019 Nov 21. pii: S0168-8278(19)30677.
    >> Share

  765. HE X, Wang Y, Fan X, Lei N, et al
    A schistosome miRNA promotes host hepatic fibrosis by targeting transforming growth factor beta receptor III.
    J Hepatol. 2019 Nov 15. pii: S0168-8278(19)30674.
    >> Share

    October 2019
  766. SUNDARAM V, Kogachi S, Wong RJ, Karvellas CJ, et al
    Effect of the clinical course of acute on chronic liver failure prior to liver transplantation on post-transplant survival.
    J Hepatol. 2019 Oct 25. pii: S0168-8278(19)30640.
    >> Share

  767. GIANNELLI V, Roux O, Laouenan C, Manchon P, et al
    Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation.
    J Hepatol. 2019 Oct 14. pii: S0168-8278(19)30603.
    >> Share

  768. BRIL F, Barb D, Lomonaco R, Lai J, et al
    Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
    J Hepatol. 2019 Oct 4. pii: S0168-8278(19)30584.
    >> Share

    August 2019
  769. BHANGUI P, Lim C, Levesque E, Salloum C, et al
    Novel Classification of Nonmalignant Portal Vein Thrombosis: A guide to Surgical Decision Making during Liver Transplantation.
    J Hepatol. 2019 Aug 20. pii: S0168-8278(19)30479.
    >> Share

    June 2019
  770. AL-DURY S, Wahlstrom A, Panzitt K, Thorell A, et al
    Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
    J Hepatol. 2019 Jun 26. pii: S0168-8278(19)30383.
    >> Share

  771. WANG J, Wang H, Peters M, Ding N, et al
    Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis.
    J Hepatol. 2019 Jun 10. pii: S0168-8278(19)30342.
    >> Share

  772. RAVICHANDRAN G, Neumann K, Berkhout LK, Weidemann S, et al
    Interferon-gamma-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30309.
    >> Share

    May 2019
  773. DE TYMOWSKI C, Depret F, Soussi S, Nabila M, et al
    Contributing factors and outcomes of burn-associated cholestasis.
    J Hepatol. 2019 May 29. pii: S0168-8278(19)30292.
    >> Share

    April 2019
  774. HARMS MH, van Buuren HR, Corpechot C, Thorburn D, et al
    Ursodeoxycholic Acid Therapy and Liver Transplant-free Survival in Patients with Primary Biliary Cholangitis.
    J Hepatol. 2019 Apr 10. pii: S0168-8278(19)30228.
    >> Share

    March 2019
  775. TSUNODA T, Kakinuma S, Miyoshi M, Kamiya A, et al
    Loss of Fibrocystin Promotes Interleukin-8-Dependent Proliferation and CTGF Production of Biliary Epithelium.
    J Hepatol. 2019 Mar 15. pii: S0168-8278(19)30146.
    >> Share

  776. JAIN V, Burford C, Alexander EC, Sutton H, et al
    Prognostic markers at adolescence in patients Biliary Atresia for liver transplantation in adulthood.
    J Hepatol. 2019 Mar 12. pii: S0168-8278(19)30143.
    >> Share

    December 2018
  777. ICHAI P, Laurent-Bellue A, Camus C, Moreau D, et al
    Liver transplantation in patients with liver failure related to exertional heatstroke.
    J Hepatol. 2018 Dec 3. pii: S0168-8278(18)32575.
    >> Share

    November 2018
  778. HIRSCHFIELD GM, Chazouilleres O, Drenth JP, Thorburn D, et al
    Effect of NGM282, a FGF19 analogue, in Primary Sclerosing Cholangitis: a Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
    J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32519.
    >> Share

    July 2018
  779. LAUTERIO A, Moioli MC, Di Sandro S, Travi G, et al
    HIV-positive to HIV-positive liver transplantation: To be continued.
    J Hepatol. 2018 Jul 23. pii: S0168-8278(18)32180.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016